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ABSTRACT 
IL-1β induces a profound and long-lasting hypoglycemia in C57BL/6J mice (wild 
type, WT) and resets glucose homeostasis at central levels. 
Intracerebroventricular (i.c.v.) injection of IL-1 at a dose that has no effect when 
injected intraperitoneally (i.p.), induces hypoglycemia, even after a glucose load. 
Interestingly, IL-1 also increases corticosterone plasma levels, although this effect 
is of shorter duration than hypoglycemia. 
Myeloid-differentiation factor 88 (MyD88) is a central adaptor molecule involved in 
IL-1 signalling, but MyD88-independent IL-1-signalling pathways have also been 
described. The first part of this work investigated if IL-1β-induced hypoglycemia 
and the increase in glucocorticoid levels are MyD88-dependent by using two 
approaches: a) administration of IL-1β into MyD88 knockout (MyD88KO) mice; 
and b) pharmacological inhibition of MyD88 in WT mice prior to IL-1β injection. No 
changes in glucose and corticosterone blood levels were detected in MyD88KO 
mice after IL-1β injection as compared to WT mice. Administration of the MyD88 
inhibitor to WT mice did not abolish the hypoglycaemic effect of IL-1. Since the 
inhibitor did not affect IL-1-induced IL-6 production either, it is possible that the 
concentration used was insufficient. However, a short-lasting hyperglycaemia was 
observed when the inhibitor was injected alone to WT mice. Particularly the 
results obtained in MyD88KO mice show that IL-1β-induced hypoglycemia and the 
increase in corticosterone concentrations depend on this adaptor molecule. The 
second part of this thesis studied cerebral energy metabolism during IL-1β-
induced hypoglycemia, and compared it to the effects of a similar hypoglycemia 
induced by insulin, and to euglycaemic conditions. In vivo cerebral H1-magnetic 
resonance spectroscopy (MRS) was used for this purpose. It was found that, as 
opposite to insulin, the concentrations of lactate, creatine, and N-acetyl aspartate, 
in relation to those of choline, are increased during IL-1β-induced hypoglycemia. 
These results provide further evidence that IL-1β injected peripherally influences 
cerebral energy metabolism in parallel to a long-lasting and profound 
hypoglycemia. Besides its relevance for normal physiology, these results might be 
important during psychiatric diseases during which impairments of cerebral energy 
metabolism are observed, but also several immune-derived cytokines are 
involved. 
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ZUSAMMENFASSUNG 
IL-1β induziert eine tiefe und lang anhaltende Hypoglykämie bei C57BL/6J 
Mäusen und führt zu einer Neueinstellung des Blutzuckersollwerts im Gehirn. 
Intrazerebroventrikuläre IL-1-Injektion, in einer Dosis die keinen Effekt hat wenn 
sie peripher injiziert wird, induziert eine Hypoglykämie, die sich nach 
Glukosebolusgabe erneut einstellt. Interessanterweise führt IL-1 außerdem zu 
erhöhten Plasmacorticosteronwerten, auch wenn dieser Effekt kürzer anhält als 
die Hypoglykämie. Ein zentrales Adapterprotein des IL-1-Rezeptors zur 
intrazellulären Signaltransduktion ist der Myeloid-differentiation Faktor 88 
(MyD88). Es gibt jedoch auch MyD88-unabhängige Signalkaskaden von IL-1. Der 
erste Teil dieser Arbeit untersucht, ob die von IL-1β hervorgerufene Hypoglykämie 
und die erhöhten Corticosteronwerte abhängig von MyD88 sind. Hierfür wurden 
zwei verschiedene Anätze gewählt: a) IL-1β-Injektion in MyD88 knockout Mäuse; 
und b) Verabreichen eines pharmakologischen MyD88-Inhibotrs vor IL-1β-
Injektion. Im Vergleich zu WT Mäusen entwickelten MyD88KO Mäuse weder eine 
Hypoglykämie noch erhöhte Corticosteronwerte. Die Injektion des Inhibitors 
verhinderte hingegen nicht die Entwicklung einer IL-1β induzierten Hypoglykämie, 
führte aber zu einem kurzfristigen Anstieg der Blutzuckerwerte. Da außerdem die 
Produktion von IL-6 durch den Inhibitor nicht beeinflusst wurde, ist davon 
auszugehen, dass die verabreichte Konzentration zu gering war. Vor Allem die 
Versuche mit den MyD88KO Mäusen zeigen, dass MyD88 notwendig ist, um eine 
IL1-induzierte Hypoglykämie entwickeln zu können. Im zweiten Teil der Arbeit 
wurde der Energiestoffwechsel im Gehirn während IL-1 induzierter Hypoglykämie 
untersucht und mit Insulin induzierter Hypoglykämie und Euglykämie verglichen. 
Hierfür wurden in vivo H1 Magnetresonanzspektroskopien (MRS) durchgeführt. 
Die Konzentrationen von Kreatin, Laktat und N-Acetyl Aspartat im Vergleich zur 
Cholinkonzentration waren bei IL-1 induzierter Hypoglykämie höher als bei 
Insulin-induzierter Hypoglykämie oder Euglykämie.  Dies ist ein weiterer Hinweis 
darauf, dass peripher injiziertes IL-1 den zerebralen Energiestoffwechsel so 
beeinflusst, dass es zu einer charakteristischen Hypoglykämie kommt. Abgesehen 
von der physiologischen Relevanz könnten diese Prozesse auch eine Rolle bei 
psychiatrischen Erkrankungen führen, bei denen es zu Veränderungen des 
zerebralen Energiestoffwechsels kommt und Cytokine involviert sind. 
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1 INTRODUCTION 
1.1 General background 
Interleukin-1 (IL-1) was originally described as leukocyte-derived factor able to 
induce fever (Dinarello, 2010). Experiments with purified supernatant of activated 
leukocytes showed various different properties of the so-called human leukocytic 
pyrogen such as induction of hepatic acute-phase proteins, activation of 
lymphocytes and induction of prostaglandin synthesis (Dinarello, 2010). The 
cloning of IL-1 finally allowed to prove that the above described effects were all 
induced by a single molecule, and additional effects such as bone marrow 
stimulation (Smith et al., 1993) and induction of type-1 diabetes (Bendtzen et al., 
1986) were described. Another effect of IL-1 is the induction of a profound and 
long-lasting hypoglycemia and the resetting of glucose homeostasis at central 
levels (del Rey and Besedovsky, 1987; del Rey and Besedovsky, 1992; del Rey et 
al., 2006). Even after a glucose load, IL-1β-induced hypoglycemia lasts longer 
than insulin induced-hypoglycemia. Furthermore, when glucose is injected after 
IL-1β hypoglycaemic values are quickly regained and maintained for hours (del 
Rey et al., 2006). This change of set point must take place at cerebral levels and 
one possibility is that it is caused by a change in energy substrate transport or 
metabolism in neurons. Magnetic resonance spectroscopy was used in this work 
to evaluate cerebral energy metabolism under IL-1β-induced hypoglycemia in 
vivo. Furthermore, it was studied whether the myeloid differentiation factor 88 
(MyD88), a central downstream protein mediating the IL-1 receptor I (IL-1RI) 
signalling, is involved in the hypoglycaemic effect of the cytokine.  
1.2 The IL-1 family 
IL-1β belongs to the IL-1 family consisting of 11 cytokines: IL-1α, IL-1β, IL-1 
receptor antagonist (IL-1ra), IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36ra, IL-37 
and IL-38. It is considered that these Interleukins originate from the same 
ancestral gene because they share a large homology in their gene structure and 
key amino acid structure, so that each protein forms a 12-stranded β-barrel 
(Dinarello, 1991, 2011; Rupp et al., 1986; Sims and Smith, 2010). 
The gene encoding for IL-1α has 10.5 kilobases (kb), whereas the IL-1β gene 
consists of 7.8 kb. 7 exons of both genes form the mRNA, which is translated to a 
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Pro-IL-1 protein of 31Kilodalton (kDa) (Dinarello, 1991). In the case of IL-1β, this 
pro-IL-1-peptide is intracellularly cleaved by Caspase-1 to mature IL-1β of 15 
kDA, which is the form finally released (Dinarello, 2005). Pro-IL-1α remains within 
the cell or at the cell surface. So either pro-IL-1α is released after cell death and 
then activated, or membrane bound IL-1α gets cleaved by calpain to its soluble 
form (Dinarello, 1996). Furthermore, pro-IL-1α is able to translocate into the 
nucleus and act as transcription factor (Dinarello, 2011). 
IL-1 was first described as an endogenous pyrogen with the ability to generate 
fever (Atkins, 1960). It plays a central role in host-defence by activating various 
cell types such as fibroblasts, thymocytes and B- and T-lymphocytes. Moreover, 
IL-1 induces the synthesis of other cytokines, such as IL-2 and IL-6 as well as its 
own production and leads to the expression of different genes, such as 
Cyclooxygenase-2 (COX-2), inducible NO-Synthetase (iNOS) and acute-phase 
proteins, and also growth factors, such as platelet derived growth factor (PDGF), 
nerve growth factor (NGF) and Insulin-like growth factor 1 (IGF-1) (Dinarello, 
1996). In addition, IL-1 influences several neuro-endocrine and metabolic 
pathways. 
IL-1ra is a physiologically occurring antagonist of IL-1. It binds to IL-1 receptor 
type 1 (IL-1RI) but does not lead to heterodimerization (see 1.2.1) which is 
essential for intracellular signalling (Garlanda et al., 2013). 
1.2.1 IL-1 receptors and signalling 
There are two subtypes of IL-1 receptors (IL-1R), but only the type 1 receptor 
transduces an intracellular signal after binding IL-1. The type 2 IL-1 receptor (IL-
1RII) lacks an intracellular signalling domain and thus serves as a decoy receptor. 
IL-1RII, like IL-1ra, contributes to regulate IL-1 effects by binding the free cytokine 
thus limiting the effects of soluble IL-1 (Dinarello, 2011). IL-1-signalling pathways 
are complex and include a variety of intracellular kinases, which lead to the 
activation of nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1). These 
factors control most of the pro-inflammatory effects induced by IL-1 (Garlanda et 
al., 2013). Only the signalling pathways essential for this work will be described 
below. For a detailed review of IL-1 signalling see Weber et al., 2010. 
After binding IL-1, the IL-1-IL-1RI complex recruits the IL-1 receptor accessory 
protein (IL-1RacP), which then binds the myeloid differentiation primary response 
factor 88 (MyD88) to the intracellular Toll- and IL-1R-like domain (TIR domain, 
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Figure 1). This TIR domain is common to all Toll-like receptors (TLRs) and the IL-
1RI. The recruitment of MyD88 occurs after ligand binding of IL-1RI and all TLRs, 
with the exception of TLR3 (Akira and Takeda, 2004). MyD88 leads to 
phosphorylation and activation of several downstream kinases such as IRAK-4, 
Src and the mitogen-activated kinases (MAPK) (Davis et al., 2006; Kenny and 
O'Neill, 2008). 
Recent evidence showed that IL-1 can also signal via a MyD88-independent 
mechanism (Davis et al., 2006; Kenny and O'Neill, 2008). Inhibition of MyD88 by a 
synthetic peptide blocking the TIR domain for MyD88 recruitment leads to IL-1-
induced activation of Akt-Kinase via Posphinositol-3 kinase (PI3K). A direct 
interaction between the p85 subunit of PI3K and the IL-1RI/IL-1RacP complex is 
described in this publication. The results were confirmed using neurons from 
MyD88-deficient mice (Davis et al., 2006). Section 1.2.3 describes how the 
PI3K/Akt pathway elicits neuroprotective effects (Diem et al., 2003; Tsakiri et al., 
2008). 
IL-1β-induced activation of Src in neurons leads to expression of IL-6 and to an 
increased activation of NMDA receptors resulting in an augmented Ca2+-influx and 
increased glutamate- or NMDA-induced cell death. This signalling pathway is 
MyD88-dependent (Davis et al., 2006; Viviani et al., 2003). Interestingly, IL-1β 
induces IL-6 expression in glia cells by the “classical” signalling pathway via 
MyD88, MAPK and NFϰB (Parker et al., 2002). Furthermore, higher 
concentrations of IL-1β are needed to induce IL-6 production in glia as compared 
to neurons (Tsakiri et al., 2008). 
Recently, a splicing variant of IL-1RacP called IL-1RacPb has been described. It 
signals independently of MyD88 and is expressed in hippocampal neurons but not 
in astrocytes. RacPb is not only necessary for Src phosphorylation and activation, 
but it can also induce Src phosphorylation when transfected into astrocytes. Src 
phosphorylation peaks at low doses of IL-1, corresponding to facilitation of long-
term potentiation by IL-1β at physiological cerebral concentrations (Huang et al., 
2011). 
Moreover, there is evidence of effects of IL-1β that are independent of the IL-1RI. 
In retinal ganglion cells, IL-1β-induced changes in sodium and potassium fluxes 
can be observed, which are not blocked by IL-1ra (Diem et al., 2003). 
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1.2.2 MyD88 
MyD88 is the main intracellular adaptor molecule for all receptors belonging to the 
TLR/IL-1R (TIR) family with the exception of TLR3 (Akira and Takeda, 2004). 
Even though there are some MyD88-independent signalling pathways, MyD88 is 
essential for most effects of the TIR family (Oda and Kitano, 2006). TLRs are 
essential for innate immunity since they recognize pathogen-associated molecular 
patterns (PAMPs), such as LPS (TLR4), double-stranded RNA (TLR3) or bacterial 
Flagellin (TLR5) (Akira and Takeda, 2004). Hence TLRs are responsible for the 
first response of the immune system to intruding bacteria, viruses or parasites 
(O'Neill and Bowie, 2007). Accordingly, the response to IL-1 or to PAMPs 
detected by TLRs using MyD88 as adaptor protein is disturbed in MyD88-deficient 
mice (MyD88 KO mice). This results in an increased susceptibility to gram positive 
(e.g. Staphylococcus Aureus, Takebuchi et al., 2000), gram negative (e.g. 
Ehrlichia muris, Koh et al., 2010), parasitic (e.g Toxoplasma gondii, Scanga et al., 
2002) or viral (lymphocytic choriomeningitis virus (Zhou et al., 2005)) infections. 
Increased susceptibility in this case implies increased concentrations of 
microorganisms in blood and other organs, decreased pro-inflammatory reactions, 
such as cytokine production and splenomegaly, or increased death rates. As 
expected, MyD88 KO mice show a hypo-responsiveness to LPS, as evaluated by 
decreased cytokine production, septic shock and death (Kawai et al., 1999), as 
well as an impaired IL-1 response resulting in no detectable IL-6 and TNF-α levels 
in plasma and impaired IL-1-induced T-cell proliferation (Adachi et al., 1998). 
However, MyD88 KO mice show no obvious abnormalities up to 20 weeks of age 
as compared to wild type (WT) C57BL/6J mice. There are no differences between 
MyD88 KO mice and C57BL/6J mice at 16 weeks of age concerning food intake, 
body weight (b.w.) and locomotor activity, but the same study showed an increase 
in fasting blood glucose levels in MyD88 KO mice (Hosoi et al., 2010). Raetzsch 
et al. showed that TLR4 and MyD88 are essential for LPS-induced hypoglycemia 
(Raetzsch et al., 2009). This might be due to the loss of LPS-induced IL-1 
production, which plays a major role in LPS-induced hypoglycemia, as shown by 
del Rey et al. C57BL/6J mice that received LPS and IL-1ra injected i.p. showed 
statistically significant higher blood glucose levels than animals that received LPS 
alone (del Rey et al., 2006). 
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Figure 1 Different mechanisms of IL-1β signalling. IL-1β signals via IL-1RI-RacP complex 
MyD88-dependently, which leads to activation of NFκB and AP-1 eliciting a pro-inflammatory 
response. The MyD88-independent pathway of the IL-1RI-RacP complex causes the closure of 
NA+- and K+-channels and neuroprotection via activation of p38 MAP-kinase and PI3-kinase. The 
signalling of IL-1RAcPb is neuron specific. It activates SRC-kinase leading to phosphorylation of 
NMDA-receptors and increased Ca2+-influx into the neuron. 
1.2.3 IL-1β and the brain 
IL-1β influences the brain at different levels. It leads to the activation of the 
hypothalamus-pituitary-adrenal (HPA) axis, resulting in increased blood levels of 
ACTH and corticosterone. This effect is not due to IL-1-induced fever or the 
induction of other cytokines, such as tumor-necrosis-factor (TNF)-α or to T-cell 
derived cytokines such as IL-2 (Besedovsky et al., 1986) but is exerted directly in 
the hypothalamus at the level of corticotropin-releasing factor liberating neurons 
(Berkenbosch et al., 1987; Sapolsky et al., 1987). 
IL-1β, together with other cytokines, such as IL-6 and TNF-α, is also involved in a 
phenomenon called “sickness behaviour”. Sickness behaviour is characterized by 
malaise, fatigue, anorexia, joint and muscle aches, coldness, fever and a change 
in the endocrine status (Konsman et al., 2002), which frequently occur in case of 
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viral or bacterial infections and allows the body an efficient way to combat the 
intruding microorganisms and to better deal with the infection (Dantzer, 2009). 
IL-1 plays a critical role in neuronal injury due to trauma or insult and in 
neurodegenerative disorders. Application of IL-1 in ischemic areas leads to 
increased neuronal death, whereas IL-1ra administration decreases neuronal 
death. The mechanisms by which IL-1β contributes to neuronal damage remain to 
be elucidated, but the damage caused by the cytokine seem to be related to its 
pro-inflammatory properties or to possible changes in glutamatergic calcium influx 
(Allan et al., 2005).  
However, there is evidence that IL-1 can also be neuroprotective. For example 
intravitreous injection of 4ng IL-1β protects retinal ganglion cells from death after 
optic nerve axotomy (Diem et al., 2003). This neuroprotective effect of IL-1 is 
exerted via the phosphinositol-3-kinase/Akt pathway. In the same work it was 
shown in vitro that IL-1β induces an IL-1RI-independent change of sodium and 
potassium currents via neuronal cell membrane. This decrease of ion-fluxes was 
counteracted by a specific antibody to IL-1 but not by IL-1ra (Diem et al., 2003). In 
vitro incubation of primary rat astrocytes with IL-1β leads to high mobility group 
box 1 (HMGB1) release, a nuclear protein known to contribute to recovery from 
neuronal stroke (Hayakawa et al., 2010). In a mouse model of Alzheimer’s 
disease, it has been shown that transgenic sustained IL-1β production mitigated 
amyloid pathology and plaque size (Matousek et al., 2012). Neuronal long time 
survival was reduced after injection of kainic acid (KA), which induces 
excitotoxicity by activating glutamatergic AMPA-receptors, into IL-1R-RacPb 
deficient mice (Gosselin et al., 2013). Thus, whether IL-1 exerts neuroprotective or 
neurotoxic effects depends on the specific pathologic or physiologic 
circumstances, on the time point of action and on its concentration. 
Another brain function that is influenced by IL-1β is hippocampus-dependent 
memory. Gibertini et al. showed that infection and intraperitoneal (i.p.)-injection of 
IL-1β in pyrogenic concentrations lead to an impairment of spatial memory in the 
Morris water maze test (Gibertini et al., 1995). Other experiments confirmed these 
findings with different memory paradigms (for review see Pugh et al., 2001). 
These experiments, however, focussed on exogenous application of IL-1 in 
concentrations comparable to those under inflammatory conditions, and therefore 
cannot be used to explain the influence of IL-1β on learning under physiological, 
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healthy conditions. LTP, considered as model of the cellular mechanisms 
underlying hippocampal learning, induces IL-1β gene expression in the 
hippocampus in vitro and in vivo (Schneider et al., 1998). Moreover, inhibition of 
IL-1β by IL-1ra leads to a reversible inhibition of LTP maintenance in the 
hippocampus (Schneider et al., 1998), showing that IL-1β plays a critical role in 
LTP. Further evidence of the influence of IL-1β on learning was provided by Avital 
et al, who showed that IL-1RI knock-out mice display deficits in the Morris water 
maze test as compared to wild-type mice (Avital et al., 2003). Yirmiya et al. 
showed that transgenic expression of IL-1ra in rats leads to a poorer performance 
in the same learning paradigm and a poorer passive avoidance response, 
whereas i.c.v injection of 10ng IL-1β causes memory improvement in the passive 
avoidance response (Yirmiya et al., 2002). Del Rey et al. showed that a brain-
borne cytokine network is not only activated during LTP maintenance but also 
during learning a hippocampus-dependent task. The expression of IL-1, IL-18, IL-
1ra and IL-6 genes is increased in defined regions of the hippocampus during 
learning in parallel to decreased IL-1ra expression in the prefrontal cortex. This 
might play a role in certain pathological states, in which the hippocampus and the 
prefrontal cortex are involved, such as schizophrenia or Alzheimer’s disease (del 
Rey et al., 2013). Thus, it seems that IL-1β in physiologically healthy conditions is 
needed for hippocampal LTP and spatial memory, whereas in sickness and 
infection it leads to hippocampal memory impairment and inhibits LTP 
(Besedovsky and del Rey, 2011). LTP maintenance is dependent on changes in 
neuronal gene expression (Lynch, 2004). Thus, it seems more likely that LTP 
induces IL-1β production, which then influences neuronal gene expression in a 
para- or autocrine way and thereby helps to maintain LTP. 
IL-1β can also alter neurotransmitter concentrations in different parts of the brain 
(Besedovsky and del Rey, 1996) that correlate temporarily with metabolic and 
endocrine changes. It could be shown that IL-1β reduces noradrenalin 
concentrations in the hypothalamus, the brainstem and the spinal chord of rats 
(Kabiersch et al., 1988). Cerebral noradrenergic neurons are known to play a 
crucial role in the regulation of glucose metabolism, including glucocorticoid 
secretion and blood glucose levels (Foscolo et al., 2003; Leibowitz, 1988; Ritter et 
al., 2006). Furthermore, IL-1β-induced hypoglycemia in mice is paralleled by 
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increased serotonin concentrations in the hypothalamus without evident changes 
in insulin plasma levels (Ota et al., 2009).  
The results discussed above implicate that peripheral cytokines interact with the 
brain. The question of how peripherally injected or produced cytokines induce 
changes at brain level is not yet fully understood. Two main routes of 
communication have been proposed: a quick neuronal route via afferent nerves of 
the autonomous nervous system, for example the vagus nerve, and a slower 
humoral route affecting circumventricular organs, the choroid plexus or leading to 
a signalling via brain vessel endothelia (Dantzer, 2009). Neurons in the vagal 
nerve express IL-1RI, and intravenous IL-1β injection results in c-fos expression in 
neurons in the nodose ganglion, reflecting neuronal activation (Ek et al., 1998). 
These results were confirmed by experiments showing that subdiaphragmal 
vagotomy decreases the behavioural effects of peripherally injected IL-1β (Bluthe 
et al., 1996). 
The humoral communication pathway is linked to prostaglandins. Injection of 
cyclooxygenase-2 (COX-2) inhibitors leads to diminished fever response and HPA 
activation by IL-1β (Parsadaniantz et al., 2000). COX-2 is necessary for the 
inflammation-induced synthesis of prostaglandins. This shows that prostaglandins 
are at least in part responsible for the behavioural and endocrine changes 
induced by IL-1β injection. Furthermore, brain vessels express IL-1RI and show 
increased COX-2 expression after IL-1β injection (Cao et al., 1997; Parsadaniantz 
et al., 2000). Gosselin and Rivest showed that endothelial MyD88 is necessary for 
IL-1-induced neuronal activation and corticosterone release (Gosselin and Rivest, 
2008). However, IL-1β-induced behavioural changes do not depend on 
prostaglandins alone, but also on effects of cerebral IL-1, since the effects of 
injected IL-1β could be totally abolished by simultaneous i.c.v. injection of IL-1ra 
(Plata-Salaman and Ffrench-Mullen, 1992). Furthermore, experiments with radio-
labelled IL-1 showed that circulating IL-1 enters the brain via a saturable transport 
system and elicits direct effects in the CNS (Banks et al., 2002; Banks and Kastin, 
1991; Banks et al., 1989). For an extensive review of cytokine-brain interaction 
see McCusker and Kelley, 2013. 
1.2.4 IL-1β and energy metabolism 
IL-1β induces a profound and long-lasting hypoglycemia in mice. This effect is 
insulin-independent and is not due to loss of glucose in the urine or decreased 
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food intake (del Rey and Besedovsky, 1987; del Rey and Besedovsky, 1992; del 
Rey et al., 2006). Part of this hypoglycemia can be explained by IL-1β-induced 
glucose uptake by different peripheral tissues, for example adipocytes, fibroblasts, 
intestinal macrophages and chondrocytes (Bird et al., 1990; Fischereder et al., 
2003; Fukuzumi et al., 1996; Garcia-Welsh et al., 1990; Gould et al., 1995; 
Shikhman et al., 2004).  
Glucose uptake is mediated by increased expression of different glucose 
transporters (GLUT), depending on the tissue. In ovarian granulosa cells, for 
example, IL-1β induces an increase of GLUT-1 and GLUT-3 expression (Kol et 
al., 1997), whereas in chondrocytes it induces GLUT-1 and GLUT-6 expression 
and incorporation into the cell membrane (Shikhman et al., 2004).  
Additionally, IL-1β inhibits gluconeogenesis in the liver by inhibiting the 
phosphoenolpyruvate-carboxykinase and leads to a reduced glycogen content in 
the liver (del Rey et al., 1998; Metzger et al., 2004). 
Some studies suggest that IL-1β may induce hypoglycemia not only in rodents, 
but also in humans, since low doses of LPS induce a transient hypoglycemia 
(Bloesch et al., 1993) and increase glucose utilization (Agwunobi et al., 2000). In a 
phase I trial IL-1β induced a transient hypoglycemia in patients (Crown et al., 
1991). 
Besides peripheral mechanisms, there is evidence that central mechanisms also 
contribute to IL-1β-induced hypoglycemia:  
(a) C3H/HeJ mice react to IL-1β injection with hypoglycemia that lasts at least 
eight hours, whereas counterregulatory hormones such as glucagon and 
corticosterone return to normal levels after four hours (del Rey and Besedovsky, 
1987; Ota et al., 2009);  
(b) i.c.v. injection of IL-1ra to C57BL/6J mice simultaneously injected with IL-1β 
i.p. leads to a less profound hypoglycemia than in animals injected with IL-1β 
alone (del Rey et al., 1998);  
(c) IL-1β-injected mice return to hypoglycemia after a glucose load. This effect is 
abolished by simultaneous i.c.v. injection of IL-1ra (del Rey et al., 1998; del Rey et 
al. 2006);  
(d) IL-1β leads to a decrease of blood glucose values in insulin resistant db/db 
deficient mice. These animals return to decreased blood glucose values after a 
glucose load (del Rey et al., 2006). 
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So far it is unknown if IL-1β changes glucose uptake and consumption in neurons. 
However, evidence exists that IL-1 increases glucose metabolism and glucose 
uptake in astrocytes (Vega et al., 2002). The role of astrocytes in cerebral energy 
metabolism and in neuronal energy supply is not yet fully understood, but recent 
evidence indicates that astrocytes might play a central role in cerebral and 
neuronal energy metabolism (see 1.4). The predominant glucose transporter in 
neurons is GLUT-3, whereas glial cells, such as astrocytes, mainly express 
GLUT-1 (Simpson et al., 2008; Vannucci et al., 1997). The expression of both 
isoforms is increased during phases of increased cerebral glucose utilization 
(increased synaptic connectivity, brain maturation), whereas it decreases in states 
of decreased cerebral glucose utilization (e.g. Alzheimer’s disease, Simpson et 
al., 2008; Vannucci et al., 1997). One possibility would be that IL-1 induces 
changes in the expression and incorporation of GLUTs in the cell membrane of 
neurons and astrocytes, as it does in other tissues (Metzger et al., 2004; 
Shikhman et al., 2001), which might help to keep the intracellular glucose 
concentration at the same level during extracellular hypoglycemia. In contrast to 
activation of the HPA-axis, the hypoglycaemic effect of IL-1 seems to be 
independent of prostaglandins, since hypoglycemia is not influenced by COX 
inhibitors (Besedovsky and del Rey, 1987). 
1.3 Corticosterone 
Corticosterone is the most important glucocorticoid in mice. Glucocorticoids 
influence various immunological responses. For example, they diminish 
endothelial permeability, inhibit cytokine production and decrease lymphocyte 
clonal expansion (Zen et al., 2011). Glucocorticoid levels increase after endotoxin 
challenge and act as inhibitors of the systemic or local inflammation (Zen et al., 
2011). Increased corticosterone blood levels are also observed during specific 
immune responses and contribute to regulate the magnitude and specificity of the 
immune response. (Besedovsky et al., 1975; del Rey et al., 1984)  Thus, 
glucocorticoids play an important role in regulating inflammation and immunity, 
and in regaining the physiological, healthy state after infection (Besedovsky and 
del Rey, 2006, for review see Besedovsky and del Rey 1996). It is known since a 
long time that the increase in glucocorticoid levels during an immune response is 
mediated by immune-derived products (Besedovsky et al., 1985). IL-1 was the 
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first purified cytokine shown to stimulate the HPA axis. IL-1 injection leads to an 
increase in ACTH and corticosterone plasma levels. This increase is dose-
dependent at least up to a dose of 1 µg/mouse and peaks two hours after injection 
(Besedovsky et al., 1986). At least the acute IL-1-induced increase of ACTH and 
glucocorticoid levels is due to effects at hypothalamic levels, by stimulation of 
CRF release into the hypothalamic-pituitary portal system (Berkenbosch et al., 
1987). IL-1-induced prostaglandin synthesis at central levels might be responsible 
for the hypothalamic effects (Turnbull and Rivier, 1999). 
1.4 Astrocyte-Neuron-Lactate-Shuttle 
Following the classical view of neuronal energy metabolism, the main fuel for 
neurons is supplied by glucose, which is oxidized via glycolysis to pyruvate and 
then delivered into the tricarboxylic acid (TCA) cycle. The reducing equivalents 
are then reoxidized by the electron transport chain, the major ATP-producing 
mechanism under aerobic circumstances. 
In 1994, Pellerin and Magistretti introduced a new concept of cerebral energy 
metabolism, named the astrocyte-neuron-lactate-shuttle hypothesis (ANLSH, 
(Pellerin and Magistretti, 1994). It was shown that glutamate uptake into 
astrocytes increases glycolysis and lactate release. These results support the 
hypothesis that astrocytes are the main metabolizers of cerebral glucose and 
release lactate, which is then taken up by neurons and further metabolized 
(Pellerin and Magistretti, 1994). It has been shown in different in vitro and in vivo 
studies that astrocytes are better suited for glycolysis and lactate production than 
neurons, whereas neurons are more likely to metabolize lactate than astrocytes 
(Pellerin, 2008). Lovatt et al. showed in a transcriptome study that glycolytic 
enzymes are expressed abundantly in astrocytes as compared to neurons (Lovatt 
et al., 2007). Furthermore, they showed that the expression of lactate-
dehydrogenase b (LDHb) is increased more than 13-fold in astrocytes relative to 
neurons, whereas expression of LDHa is increased 8-fold in neurons relative to 
astrocytes. In principle, LDHb catalyses the hydrogenation of pyruvate to lactate, 
whereas LDHa catalyses the reverse reaction. Thus, astrocytes are better suited 
to produce lactate from pyruvate, whereas neurons are more suited to produce 
pyruvate from lactate, providing arguments in favour of the ANLSH. In the same 
study, using radio-labelled glucose, it was shown that astrocytes produce lactate 
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directly from glycolysis. Surprisingly, some of the lactate originated from TCA-
cycle intermediates, suggesting that not all glucose was metabolized to lactate, 
but some was transferred to the TCA cycle (Lovatt et al., 2007). 
It is still controversial if and how energy metabolism is compartmentalized in the 
brain between astrocytes and neurons. It is still unclear whether glucose is 
primarily taken up by neurons or astrocytes, if lactate is shuttled between these 
cells and if lactate contributes to brain energy metabolism in a significant amount 
at all (Chih et al., 2001; Mangia et al., 2011; Pellerin, 2008). 
1.5 Central glucose-regulation 
A necessary condition for central glucose regulation is the presence of cells able 
to sense glucose or its metabolites to assess the state of energy metabolism in 
the brain and in the whole body. These glucose-sensing neurons are found in 
different parts of the brain such as the brain stem and different nuclei of the 
hypothalamus as first shown by Oomura in 1969 (Oomura et al., 1969). Glucose-
sensing neurons can be divided into glucose-excited (GE) neurons, which 
depolarise when glucose concentration rises and hyperpolarise when glucose 
concentration decreases, and glucose-inhibited (GI) neurons, which hyperpolarise 
when glucose concentration rises and depolarise when glucose concentration 
decreases (Burdakov et al., 2005). 
Glucose-sensing neurons can be classified based on the neurotransmitter they 
release or on their location: 
(a) Glucose-sensing neurons, which release products of the pro-
opiomelanocortin (POMC) gene or neuropeptide Y (NPY) upon 
depolarisation are found in the arcuate nucleus of the hypothalamus. These 
neurons play a crucial role in food intake and catabolic or anabolic energy 
metabolism and do not only react to changes in glucose concentrations but 
also to leptin or insulin, hormones that indicate the state of feeding and 
energy storage (Cone et al., 2001). 
(b) Orexin-producing glucose-sensing neurons in the lateral hypothalamus play 
a role in feeding behaviour (possibly mediated via the NPY/POMC system) 
and the regulation of sleep and wakefulness (Sakurai, 2007).  
(c) Concerning counterregulation to hypoglycemia, glucose-sensing neurons in 
the ventromedial hypothalamus (VMH) are of great importance. Lesions in 
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the VMH cause a significant decrease in counterregulatory hormones 
during hypoglycemia compared to lesions in the lateral hypothalamus or 
sham-operated animals (Borg et al., 1994). Moreover, local infusion of D-
glucose into the VMH results in a decreased release of counterregulatory 
hormones during a hypoglycaemic clamp (Borg et al., 1997), whereas 
infusion of 2-deoxyglucose into the VMH induces an increase in 
hypoglycaemic counterregulatory hormones. 2-deoxyglucose enters cells 
as glucose but is not further metabolized and therefore causes intracellular 
hypoglycemia (Borg et al., 1995).  
GE- and GI-neurons can be identified in the VMH. The depolarisation of GE-
neurons is mediated by an ATP-sensitive K+-channel (KATP-channel). KATP-
channels close at high concentrations of ATP which leads to depolarisation of the 
respective cell (Ashford et al., 1990). Infusion of diazoxide, a potassium channel 
opener, into the VMH augments counterregulatory responses to hypoglycemia, 
whereas infusion with sulfonylurea inhibits counterregulatory responses by closing 
KATP –channels (Evans et al., 2004; McCrimmon et al., 2005; Sherwin, 2008). 
These findings indicate that excitation of GE-neurons leads to decreased 
hypoglycaemic counterregulation, whereas hyperpolarisation of GE-neurons in the 
VMH induces hypoglycaemic counterregulation. Furthermore, it could be 
hypothesised that glucose metabolites might be able to influence glucose-sensing 
neurons as well. In fact, lactate stimulates GE-neurons in vitro (Song and Routh, 
2005) and lactate infusion into the VMH leads to a decrease of epinephrine, 
norepinephrine and glucagon plasma concentrations in hypoglycaemic rats and 
an 8-fold increase in glucose infusion rate needed to maintain hypoglycemia in an 
euglycaemic/hypoglycaemic clamp (Borg et al., 2003). 
1.6 Magnetic resonance spectroscopy 
1.6.1 Operation principle 
The basic principle of magnetic resonance spectroscopy (MRS) as used in this 
study is the proton (H1) magnetic resonance imaging technique. 
In H1 magnetic resonance imaging (MRI), the spin of hydrogen nuclei consisting of 
a single proton is used to induce alterations in an external magnetic field. The spin 
of atomic nuclei is an innate property of the respective atom. The spin itself is not 
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detectable, but since the nucleus has a positive charge, the spinning produces a 
magnetic momentum and acts like a dipole. 
MRI devices work with different magnetic fields and electromagnetic impulses. 
The strong external magnetic field B0 induces a precession of the spin. The 
frequency of the spin precession is called Larmor-frequency. The Larmor-
frequency is specific for each nuclear isotope and proportional to the strength of 
the external magnetic field. The strong magnetic field effectuates a longitudinal 
magnetisation, which can be detected and switched in a 90° angle with a 
radiofrequency impulse of the Larmor-frequency called resonance impulse. Now 
nuclear spins do not precess longitudinally but transversally, which induces an 
alternating current of the Larmor-frequency in a reception coil. This is the MR-
signal (Weishaupt et al., 2009). 
Whereas standard MRI is used to obtain spatial information, MRS is used to 
obtain information about the chemical composition of the examined subject in 
vivo. H1 nuclei in different chemical compounds are surrounded by different 
electron clouds. These electrons lead to a slight change in the strength of the 
magnetic field that acts on the nucleus. Since the Larmor-frequency is dependent 
on the strength of the magnetic field, the result is a slight shift of this frequency. 
This shift is measured and, after different calculations, plotted on a graph with the 
chemical shift in parts per million (ppm) on the X-axis. The vertical Y-axis plots the 
relative signal amplitude. Thus, the concentration of the determined metabolites is 
proportional to the area under the curve of the respective peak (Backens, 2010). 
1.6.2 Metabolites 
N-acetyl aspartate 
N-acetyl aspartate (NAA) is present at high concentrations in the brain and gives 
the largest peak in healthy brain MRS, resonating at 2.02 ppm (Soares and Law, 
2009). It is used as a marker of neuronal integrity since its concentration 
decreases in various states of neuronal loss such as stroke, neurodegenerative 
diseases, multiple sclerosis (MS) or gliomas (Barker and Lin, 2006). Furthermore, 
it has been shown that lower concentrations of NAA correlate with higher disability 
scores in MS, indicating its usefulness as marker of neuronal function (de Stefano 
et al., 2001). However, patients with Canavan’s disease, a fatal, genetic disorder 
of NAA catabolism, show a marked increase in NAA concentration but a severe 
impairment of motor and cognitive development. Canavan’s disease is the only 
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disorder known so far that involves increased NAA concentrations, thus showing 
restrictions to the usefulness of NAA as marker for neuronal integrity (Moffett et 
al., 2007). 
Despite its high concentration in the brain, its function remains controversial. 
There are four major theories concerning the role of NAA in brain: 
a) NAA is synthesized in neurons and shuttled to oligodendrocytes, in which the 
acetyl moiety is cleaved from aspartate and used for lipid synthesis, thus serving 
for myelination; b) NAA is considered as an organic osmolyte, equalling the anion 
deficit in neurons or being used for co-transport with intracellularly synthesized 
water; c) NAA is a precursor of the dipeptide N-acetyl aspartyl glutamate (NAAG), 
a neuropeptide that influences presynaptic excitability; d) NAA is linked to 
oxidative energy metabolism. However, it is still unclear whether it plays a role in 
energy metabolism (Moffett et al., 2007). 
 
Lactate 
Lactate is the product of the lactate-dehydrogenase (LDH) reaction, when 
pyruvate is reduced to lactate while NADH is oxidized to NAD+. This reaction 
mainly occurs under anaerobic conditions. Its main function is to restore NAD+, 
which is necessary for glycolysis. In some tissues, such as the liver, the LDH-
reaction is reversed and lactate is used for glycogenesis or enters the tricarboxylic 
acid (TCA) cycle via oxidation to pyruvate. 
In MRS, the methyl group of lactate resonates at 1.31 ppm. Rises of lactate 
concentration under hypoxic conditions or states of increased anaerobic 
glycolysis, such as seizures, can be detected with cerebral MRS (Soares and 
Law, 2009). Some studies show an increase in lactate in the visual cortex under 
physiological photic stimuli (Prichard et al., 1991; Sappey-Marinier et al., 1992), 
whereas others could not reproduce these results (Merboldt et al., 1992). 
Creatine 
Creatine (Cr) is synthesized in the liver and kidney, and transported via blood to 
other tissues, where it is taken up by active transport. It acts as “energy-buffer” 
since it can be phosphorylated to phosphocreatine by the enzyme creatine kinase. 
The phosphate group of creatine phosphate (PCr) can be used to phosphorylate 
ADP to ATP, which is important in tissues with a high energy metabolism, such as 
muscle, spermatozoa or brain (Wallimann et al., 1992). 
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The methyl group of Cr and PCr resonates at 3.03 ppm. Thus Cr and PCr are not 
distinguishable by H1-MRS (Soares and Law, 2009). Although Cr concentration is 
considered to be temporally stable its concentration varies between different brain 
regions. Albeit its common use to calculate metabolite ratios (Barker and Lin, 
2006), it was not used as reference in the studies reported here since Cr is also 
involved in energy metabolism. 
Choline 
The C(NH3)3 group of Cho resonates at 3.20 ppm. The resulting peak is 
composed of soluble glycerophosphocholine, phosphocholine and free choline. 
The choline bound to macromolecules of the membranes is not detected by MRS. 
Choline levels differ between white and grey matter and change during 
pathological states. Higher choline levels might be found in tumor tissue, whereas 
its levels usually decrease in situations such as infections or degeneration 
(Soares and Law, 2009). 
1.7 Aims and objectives 
This work consists of two parts. The first part investigates the question if IL-1β-
induced hypoglycemia is MyD88-dependent. To answer that question, MyD88KO 
mice were injected with IL-1β and blood glucose and corticosterone levels were 
compared to their WT littermates, which received the same treatment. MyD88KO 
mice show no obvious abnormalities in their development as compared to WT 
mice. However, if alternative signalling mechanisms, especially in the brain, are 
developed due to the lack of MyD88 is not known. Therefore, a pharmacological 
MyD88 inhibitor was used as a second approach to answer that question. WT 
mice received either the inhibitor or a control peptide prior to IL-1β injection and 
blood glucose and corticosterone levels were measured and compared.  
The second part of this work focuses on cerebral energy metabolism under IL-1β 
induced hypoglycemia. As discussed above, IL-1β resets glucose homeostasis at 
central levels. Thus, cerebral energy metabolism must be influenced. To describe 
this and compare it to cerebral energy metabolism under insulin-induced 
hypoglycemia, WT mice were injected with IL-1β, insulin or vehicle and cerebral 
H1MRS was performed. Thus, it was possible to compare the metabolite-changes 
in vivo and during the course of hours, since MRS can be repeated several times 
in the same animal. Three of the four metabolites detected are involved, or 
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supposed to be involved, in energy metabolism. As opposed to Lac and NAA, the 
mechanisms by which Cr contributes to energy metabolism are well understood. 
According to the controversially discussed ANLS Hypothesis, astrocyte-derived 
lactate is shuttled to neurons to meet with the neuronal energy demand. NAA 
might be linked to oxidative energy demand. Cho, the fourth metabolite detected, 
is not involved in energy metabolism and used as reference substance in this 
work. 
  25 
2 MATERIAL AND METHODS 
2.1 Animals 
C57BL/6J male mice (7 week-old) were purchased from Harlan Winkelmann 
(Borchen, Germany). MyD88 KO mice were used after obtaining written 
permission from Dr. S. Akira, University of Osaka, Japan. The MyD88 KO mice for 
evaluating the MyD88-dependence of IL-1β-induced hypoglycemia were kindly 
provided by Prof. Dr. Dalpke and Dr. Bode, Institut für medizinische Mikrobiologie 
und Hygiene, Heidelberg. These MyD88KO mice have a C57BL6/J background. 
MyD88-deficient mice are fertile and breed normally. In general, breeding was 
started with one female and one male. Pups were fed by the mother until they 
were three to four weeks old. The offspring was identified by ear-marks and the tip 
of the tail was collected for genotyping. Thereafter, pups were separated from the 
mother, according to the gender, and kept in groups of not more than 4 animals 
per cage. 
All animals were housed permanently in a humidity-, temperature- and light- (12h 
cycle) controlled room. Animals were fed with normal chow diet and had access to 
food and water ad libitum. Animals were individually caged for at least 7 days 
before experiments were started. To control the health status and to accustom the 
animals to handling, mice were weighted twice a week. Only male mice between 8 
and 17 weeks of age (b.w. 20-30 g) were used for the experiments. The 
distribution in the different experimental groups was weight- and age-matched. 
Experiments were approved by the Regierungspräsidium Gießen (Aktenzeichen 
V54-19c 20-15(1) MR 20/28-Nr. 59/2007). 
2.2 Material 
The instruments, materials and software used in this work are listed in the tables 
below. 
Table 1: Instruments  
Instrument Product name Producer 
Autoclave Omega media Prestige medical, USA 
Balance METTLER PM 3000 Mettler Toledo GmbH, 
Germany 
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Blood glucose meter Accu Chek Sensor Roche Diagnostics; 
Germany 
Centrifuge 1 Table centrifuge Heraeus 
Pico 17 
Heraeus Holding GmbH, 
Germany 
Centrifuge 2 Biofuge Fresco Heraeus Holding GmbH, 
Germany 
Gradient system BGA 20S (gradient 
strength: 290 mT/m, slew 
rate: 1160 T/m/s) 
Bruker BioSpin, 
Germany 
Lactate meter Cobas Accutrend Plus 
Microplate reader Tecan Sunrise Tecan group Ltd., 
Switzerland 
MRI/MRS scanner Remote ClinScan, 7 
Tesla 
MRI/MRS scanner 
Bruker Daltonics, 
Germany 
Pipettes Pipette 0,5 - 10 µl, 200 - 
1000 µl 
Eppendorf AG, Germany 
Pipettes Pipetman 0 -20 µl, 0-
200µL 
Gilson, France 
Ear punch plier Nadox KN292B stainless 
2.0 
 
Respiratory frequency 
monitor 
Monitor respiratory 
frequency 
SA Instruments, Australia 
Spectrophotometer Ultrospec 2000 Amersham Pharmacia 
Biotech GmbH,Germany 
Surface head coil 2-channel quadrature 
surface head MRI coil 
Rapid biomedicals, 
Bruker 
Surgical blade Sterical carbon steal 
blade 
Heinz Herenz, Germany 
Water bath system Haake P5 + C10 Thermo Electron 
Cooperation 
 
Table 2 Materials 
Material Product name Producer 
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Breeding diet for mice 
 
LASQCdiet Rod16, Hihyg 
(pasteurised) 
Lasvendi, Germany 
Canula Single-use-injection 
canula 
Sterican 
B. Braun Melsungen AG, 
Germany 
Capillaries (75 µl) Haematocrit-Capillaries 
Sodium-heparinized 3,75 
U/capillary 
Hirschmann Laborgeräte, 
Germany 
Gloves Nobaglove-Latex Noba Verbandmittel 
Danz GmbH u. Co KG, 
Germany 
Microtube Microtube 0,5 ml Sarstedt, Germany 
Normal diet for mice Lasqcdiet Rod18, Hihyg 
(pasteurised) 
Lasvendi, Germany 
Pipette tips Pipette tips, 10 µl, 20 µL, 
200 µL, 1000µL 
Gilson, France 
PCR cycler 1 Hybaid Cycler Omni Gene Bioproducts, 
USA 
PCR cycler 2 Sensoquest labcycler Sensoquest, Germany 
Single-use-Syringe 1 ml Norm-ject Henke-Sass, Wolf, 
Germany 
Test stripes blood 
glucose 
Glucose test stripes Accu 
Chek Sensor Comfort 
Test 
Roche Diagnostics, 
Germany 
Test stripes blood lactate stripes for lactate Cobas 
Accutrend Plus 
Roche, Germany 
Tube 1,5 ml Micro tube 1,5 ml Sarstedt, Germany 
 
Tube 2,0 ml Micro tube 1,5 ml Sarstedt, Germany 
 
Table 3 Reagents 
Reagent Product name Producer 
Agarose Agarose ultra PURE Gibco Invitrogen, 
Germany 
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AmpliTaqGold AmpliTaqGold Applied Biosystems, 
Germany 
Base ladder GeneRuler. 100 bp DNA 
Ladder 
Fermentas, Thermo 
Scientific, Germany 
Bepanthen Bepanthen, Eye and Ear 
cream 
Bayer healthcare, 
Germany 
Diethylether Diethyl ether puriss. 
stabilized 
Sigma-aldrich, 
Germany 
DNA purification QIAquick Gel extraction 
Kit 
Qiagen, Germany 
dNTP(10 mM ) RT Kit Cat No 18064-
0220 
Invitrogen, Germany 
DTT (0,1 M) RT Kit Cat No 18064-
0220 
Invitrogen, Germany 
Ethanol Ethanol 99,8% Carl Roth, Germany 
Ethanol Ethanol 75% Riedel de Haen, 
Germany 
GelRed GelRed Nucleic Acid Gel 
Stain 
Biotium, USA 
H2O H2O ultra pure water Nanopure ultra pure 
water system, Marburg, 
Germany 
HCl Hydrochloric acid Merck, Germany 
IL-1β Human recombinant IL-
1β 
Glaxo Institute for 
Molecular Biology, 
Switzerland 
MyD88 inhibitory peptide 
 
IMG2005 Imgenex, USA 
 
Control peptide Control peptide Imgenex, USA 
Insulin Insulindetemir (Levemir 
®), 100 E (14,2 mg) per 1 
ml 
Novo Nordisk, Dänemark 
Isoflurane Isoflurane HDG9623 Baxter GmbH, Germany 
KCl Potassium Chloride Merck, Germany 
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MgCl2 Magnesium Chloride Merck, Germany 
NaCl Sodium Chloride Merck, Germany 
NaCl (0,9%) Sodium chloride solution, 
isotone 
B. Braun Melsungen AG, 
Germany 
Corticosterone ELISA kit Corticosterone ELISA IBL International GmbH, 
Germany 
Oligo dT primer Oligo d(T)12-18 Amersham Pharmacia 
Biotech GmbH, Germany 
Primer See Table 2 Tib MolBiol, Germany 
Proteinase K Proteinase K Qiagen, Germany 
Reverse transcription 
buffer (5x) 
RT Kit Cat No 18064-
0220 
Invitrogen, Germany 
RNase free DNase I RNase free DNase I 
(1U/µl) 
Epicentre, USA 
RNase free H2O RNase free H2O Qiagen, Germany 
Rox reference dye Rox reference dye Agilent Technologies, 
Germany 
SDS Sodium Dodecyl Sulfate Fluka BioChemika, now 
Sigma Aldrich, Germany 
Solution for Rnase 
decontamination 
Qiagen RNeasy Kit 
Rnase-away 
Invitrogen, Germany 
SuperScriptII (200 U/µl) RT Kit Cat No 18064-
0220 
Invitrogen, Germany 
TAE buffer Tris-Acetat-EDTA buffer Fermentas, Thermo 
Scientific, Germany 
Tango buffer (10x ) 10x Y+/Tango Tango 
buffer 
MBI Fermentas, Thermo 
Scientific, Germany 
TRIS TRIS Reagent Carl Roth, Germany 
Trizol Trizol Invitrogen, Germany 
Tween20 Polyethylene glycol 
sorbitan monolaurate 
Polyoxyethylene - 
sorbitan 
monolaurate Polysorbate 
Sigma-Aldrich, 
Germany 
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Uracil-DNA-glycosylase Uracil- DNA- glycosylase New England BioLabs, 
Germany 
 
Table 4 Software 
Software Product name Producer 
ELISA Evaluation MagellanTM Tecan Group Ltd., 
Switzerland 
Statistical Software IBM SPSS Statistics 20 IBM 
Writing Software Microsoft Office Word 
2003 
Microsoft 
2.3 Methods 
2.3.1 Gentoyping 
The genotyping was kindly carried out by Dr. A. Randolf. using polymerase chain 
reaction (PCR). PCR was conducted with the primers shown in Table 5 adapted 
from Leadbetter et al 2002 (Leadbetter et al., 2002). DNA was obtained from the 
tip of the tail. A negative control and three genotype controls (heterozygous, 
MyD88KO and MyD88 wild-type) were included in each typification round. The 
PCR was conducted in a total volume of 25 µL containing: 1µl template, 12.5 µL 
2x Taq PCR master mix kit, Quiagen, 0.2 µL of each primer (10mM) and 8.5 µL 
H2O. Sequences of the primers are shown in table 5. The cycler program was 
started with 2 minutes at 95°C followed by 30 ampli fication cycles of 95°C for 30 
sec, 60°C for 45 sec, 72°C for 45 s and finished wi th 72 °C for 5 min, using 
Sensoquest labcycler. PCR products were separated by agar gel electrophoresis. 
Samples from heterozygous mice showed two bands, one at 550 base pairs (bp) 
and one at 600 bp, samples from WT mice showed one band at 550 bp and 
samples from MyD88KO animals showed one band at 600 bp. 
 
Table 5: Primers used for PCR. 
Primer Sequence 
MyD88 forward 5' - TGG CAT GCC TCC ATC ATA GTT AAC C - 3' 
MyD88 reverse 5' - GTC AGA AAC AAC CAC CAC CAT GC - 3' 
MyD88 neo 5' - ATC GCC TTC TAT CGC CTT CTT GAC GAG - 3' 
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2.3.2 Injection 
All injections were performed i.p. Since injections were always carried out 
immediately after the first blood collection to determine basal values, mice were 
still under narcosis when injected. 
2.3.3 Blood collection 
Blood was obtained from the tip of the tail under light diethylether narcosis, with 
exception of the MRS experiments. For narcosis, animals were initially placed in a 
glass box containing a diethylether soaked towel. When the tail pinch reflex was 
abolished, the procedure was started. To maintain narcosis during the procedure, 
the neck of the mice was placed in a glass flask containing ether-soaked paper 
towels. Whole blood was used for glucose determination. An additional blood 
sample was collected in heparized hematrocrit tubes and immediately centrifuged 
at 16060 g for 10 minutes at 4°C. The plasma was al iquoted and stored at -20°C 
until further use for corticosterone determination. After blood collection, the tip of 
the tail was cauterized. 
2.3.4 Glucose determination 
Glucose determinations were performed using the AccuCheck Sensor® from 
Roche Diagnostics. For this purpose, a drop of blood (aproximately 4 µl) is directly 
placed onto the test stripe, in which glucose is oxidized to gluconolacton by the 
enzyme glucose dehydrogenase while hexacyanoferrate (III) is reduced to 
hexacyanoferrate (II). An electrode consisting of palladium re-oxides the 
hexacyanoferrate (II). The resulting electron flow correlates with the glucose 
concentration in the blood sample. The measurable concentration ranges from 10 
to 600 mg/dl. 
2.3.5 Corticosterone determination 
Corticosterone concentrations were determined in plasma using a commercially 
available ELISA kit (IBL international, Germany). The microtiter wells of this ELISA 
kit are coated with a polyclonal antibody against corticosterone. The 
corticosterone in the sample competes with horseradish-peroxidase-conjugated 
corticosterone. The higher the corticosterone concentration in the sample, the 
lesser horseradish-peroxidase-conjugated corticosterone remains bound to the 
wells after washing. After addition of the substrate Tetramethylbenzidine, the 
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intensity of the colour developed is inversely proportional to the amount of 
corticosterone in the tested sample. The standards provided with this kit range 
from 0.17 µg/dl to 8.32 µg/dl. To remain within the range of the standards, 
samples had to be diluted. Samples of IL-1β-injected wild-type animals and all 
determinations after MRS scan were diluted 1:10, all other samples were diluted 
1:3. These dilutions allowed detection of corticosterone concentrations ranging 
from 0.51 µg/dl to 24.96 µg/dl in 1:3 diluted samples and from 1.7µg/dl to 
83.2µg/dl in 1:10 diluted samples. 
2.3.6 Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) was performed in the Centre for Small 
Animal Imaging, Marburg, Germany. A 7 Tesla (T) MRI/MRS scanner (ClinScan, 
BRUKER, Bremen, Germany) using syngo MR B15 software (Siemens, Erlangen, 
Germany) with the gradient system BGA 20S (gradient strength 290 mT/m, slew 
rate 1160 T/m/s) was used to acquire MR spectral data. A 2-channel quadrature 
surface head MRI coil was used to receive the signal. Narcosis was initiated by 
placing mice into a gas chamber which was linked to an isoflurane vaporizer. For 
initiation, a mixture of 5% isoflurane and 95% room air was lead into the chamber. 
When tail pinch reflex was absent, narcosis was maintained with 1.5%-3.5% 
isoflurane and blood collection started. Narcosis was maintained during the MRS 
procedure using the same vaporizer. To monitor depth of narcosis, breath rate 
was monitored permanently and kept between 40 and 80 breaths per minute. 
After narcosis and blood collection, animals were placed on the MRI bed slider 
and fixed by the front teeth. This allowed administering isoflurane directly to the 
nose of the animals. Furthermore, animals were fixed carefully by the ears to 
minimize inaccuracy in positioning. To avoid eye drying, Bepanthen ointment 
(Bepanthen Eye and Nose ointment, Bayer, Germany) was applied onto the eyes. 
Hypothermia was prevented by a water-bath system adjusted to 42°C in the bed 
slider. Respiratory frequency was monitored by a system (SA Instruments, 
Burwood East, Australia) with a sensor placed under the chest of the animals. 
The MRS protocol starts with a localizer sequence with a repetition time (TR) of 
23 ms and an echo time (TE) of 4 ms, slice thickness 1 mm, field of view (FoV) 55 
mm and a matrix of 256 pixels to control positioning of the animal. For 
determination of the Volume of Interest (VOI), three T2 weighted sequences 
(Turbo Spin Echo, TR 2750 ms (sagital and coronar), TR 3234 ms (transversal); 
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TE 43 ms; slice thickness 0.7 mm; FoV 28 mm; FoV phase 89.6%; matrix 192; 
number of slices: sagital 17, coronar 11, transversal 20) were measured. The VOI 
(which included the third ventricle, hippocampus and striatum excluding the fourth 
ventricle and the cortex) extends 5.5 mm from bregma 1.3 mm to – 4.2 mm, 6.0 
mm right to left, 3.0 mm anterior to posterior (Figure 2). 
 
 
 
 
Figure 2 Placement of the VOI in sagittal, coronal and transversal plane (from left to right). 
Before spectroscopy was started, the stimulation frequency, signal amplitude and 
magnetic field were adjusted to keep deviation of frequency below 0.2 ppm. 
Spectroscopy was performed with a relaxation time of 3000 ms, an echo time of 
27 ms and 256 averages at full width half maximum of 46-89 Hz. The water signal 
was saturated at 200 Hz, and the spectral water suppression (2.35 ppm) was 
turned on. All spectroscopy data were post-processed with the MR scanner syngo 
MR software (Siemens, Erlangen, Germany). Post-processing included Gauß 
filter, Fourier transformation, baseline, frequency and phase corrections and 
Gaussian line shape fit. The following substances were identified: NAA at 2.02 
ppm, Cr at 3.02 ppm, Cho at 3.22 ppm and Lac at 1.33 ppm. The overall duration 
of the procedure was 35 minutes on average per scan. After MRS data 
acquisition, blood was collected and animals were placed in their individual cages 
until next scan. 
2.4 Substances and Vehicles 
IL-1β: Purified human recombinant IL-1β was kindly provided by A. Shaw (Glaxo 
Institute for Molecular Biology, Geneva, Switzerland) and diluted to the desired 
concentration with endotoxin free 0.9% NaCl containing 0.01% human serum 
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albumin (HSA). The IL-1β doses used in this work are sub-pyrogenic and do not 
affect food intake. 
Insulin: Insulin (long lasting Insulin, Levemir®, Novo Nordisk) 100 Units per ml 
(U/ml) was diluted to a concentration of 0.5 U/ml with 0.9% NaCl and administered 
i.p. at a dose of 4 U/kg bodyweight (b.w.). 
IMG2005: This is a synthetic polypeptide that inhibits MyD88 homodimerization. 
IMG2005 and its control peptide were purchased from Imgenex (San Diego, 
USA). The inhibiting peptide contains two domains. The protein transduction 
domain (PTD) allows the peptide to enter into the cell, whereas the inhibiting 
domain binds to the TIR-domain of MyD88 and inhibits its homodimerization which 
is necessary to recruit downstream kinases in the signalling cascade (Loiarro et 
al., 2005). The control peptide consists only of the PTD, therefore its molecular 
weight is lower (2361 Da) than that of IMG2005 (3100 Da). The inhibitor and its 
control peptide were dissolved and diluted in phosphate buffered saline (PBS). 
Vehicle: If not further specified 0.9% NaCl containing 0.01% HSA was used as 
vehicle. 
2.5 Experimental setups 
All experiments were started between 8:00 and 10:00 a.m. to avoid influences of 
circadian rhythm on blood glucose and corticosterone levels. Mice were weighted 
immediately before initiating narcosis. The results of glucose and corticosterone 
concentrations corresponding to the first blood sample were defined as base 
levels (time 0) in all experiments. Blood collection and glucose and corticosterone 
determinations were performed as described in sections 2.3.3, 2.3.4, and 2.3.5, 
respectively. 
2.5.1 Effect of IL-1β injection on blood glucose and stimulation of the 
HPA-axis 
After obtaining the first blood sample, either 0.2 µg IL-1β in 200 µl vehicle, insulin 
or 200 µl vehicle alone were injected i.p. Insulin (4 U/kg b.w.) was injected at a 
concentration of 0.5 U/ml, so the injected volume ranged from 160 to 280 µl, 
depending on the bodyweight. Six groups were included in this experiment: 
MyD88-deficient mice that received either IL-1, insulin or vehicle, and the 
corresponding wild-type C57 BL6/J mice. Substances were injected i.p. 
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immediately after collecting basal blood sample. Additional samples were 
obtained 2, 4, 6, 8 and 24 hours after injection (Figure 3). 
 
 
Figure 3 Experimental design to study the effect of IL-1β in MyD88 KO mice. 
Blood was taken at time 0 and either IL-1β (0.2 µg in 200µL vehicle), insulin (4 U/KG b.w.), or 
vehicle (200µL) was injected i.p. Additional blood samples were obtained at the time points 
indicated. 
2.5.2 Pharmacological inhibition of MyD88 signalling 
Immediately after obtaining a first blood sample (time 0), mice received 25µg of 
either IMG2005 or control peptide dissolved in 200µl PBS injected i.p. One hour 
later, a second blood sample was collected, and immediately after animals 
received either 0.1µg IL-1β dissolved in 200µl vehicle or 200µl of the vehicle 
alone. Thus, 4 groups were included in this study. Four additional blood samples 
were obtained every two hours afterwards (Figure 4). 
0  4 6 8 24 
 
 
Blood collection 
Time (hs) 
0.2 µg IL-1 
  200 µl vehicle 
     4 U/Kg insulin  
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Figure 4 Experimental design to study the effect of inhibiting MyD88 signalling in vivo. 
Blood was taken at time 0 and animals received either IMG2005 or the control peptide injected i.p. 
One hour later, blood was collected again and animals received either IL-1β or vehicle injected i.p. 
Additional blood samples were collected at the time points indicated. 
2.5.3 Magnetic resonance spectra of IL-1β-, insulin- and vehicle- 
injected mice 
One week prior to the experiments, animals were brought to the facilities of the 
Centre for Small Animal Imaging, Marburg for acclimatisation and caged 
individually. After the first blood collection and glucose determination, MRS data 
were acquired as described in 2.3.6. The spectrum was defined as time 0 and 
represents the basal values of the substances evaluated. Immediately after 
obtaining the first spectrum, a second blood sample was obtained and animals 
received either 0.1 µg IL1-β in 200 µl vehicle, insulin or 200 µl vehicle injected i.p. 
An insulin dose of 4 U/kg b.w. was injected i.p. at a concentration of 0.5 U/ml, so 
that the injected volume ranged from 200 to 240 µl, according to bodyweight. 
Animals were replaced in their cages until the next MRS acquisition was 
performed. Thus, the experimental design included 3 groups. Spectra were 
obtained again 2, 4, 6 and 8 hours after the first MRS recording (time 0), and 
blood was obtained before and after each scan ( 
Figure 5). To maintain the same hypoglycaemic level as that induced by IL-1β, it 
was necessary to repeat the injection of the same dose of insulin (4 U/kg b.w.) 
after 4 hours. 
0 1 3 5 7 9 
 
Blood collection 
Time (hs) 
25 µg IMG2005 
25 µg control peptide 0.1 µg  IL-1β  200 µl vehicle 
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Figure 5 Experimental design of the MRS study. After blood collection and 
glucose determination the first (basal) MRS was performed. Immediately after, 
another blood collection and glucose determination were carried out and animals 
received IL-1β, insulin or vehicle i.p. Further MRS were performed at the times 
indicated above. Immediately before and after each MRS, blood collection and 
glucose determination were carried out. Four hours after the first insulin injection, 
a second insulin injection was necessary to maintain a hypoglycemia comparable 
to that of the IL-1β injected animals. 
2.5.4 Influence of isoflurane on insulin-induced hypoglycemia 
Before the first blood collection, mice were narcotized with isoflurane as described 
above for the MRS determinations. Narcosis was maintained for 35 minutes at an 
isoflurane concentration of 2.0 %, and a second blood sample was collected. 
Immediately after, animals received either 200 µl vehicle or insulin. Insulin (4 U/kg 
b.w.) was injected at a concentration of 0.5 U/ml, so the volume injected ranged 
from 200 to 240 µl, depending on the b.w. The same procedure, but without 
injections, was repeated every two hours (narcosis, blood collection, 35 minutes 
narcosis, blood collection). Since the effect of insulin vanishes after 4 hours, this 
group of mice received a second insulin injection after 4 hours (Figure 6). 
 
Blood collection, blood glucose determination 
Time (hs) 
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0.1 µg IL-1 
  200 µl vehicle 
   4 U/Kg insulin
  
 
 4 U/Kg insulin
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Figure 6 Experimental setup: effect of isoflurane on glucose levels. Blood was collected and 
blood glucose determined (time 0). After 35 minutes of isoflurane narcosis and another blood 
collection and glucose determination, the animals received either Insulin or vehicle injected i.p. 
Further isoflurane narcosis followed at the time points indicated above. Immediately before and 
after each narcosis, blood was collected and glucose determined. A second insulin injection four 
hours after the first one was necessary to maintain hypoglycemia at levels comparable to those of 
the hypoglycemia induced by IL-1β. 
2.6 Statistical analyses 
The program SPSS version 20 was used for statistical analyses. For experiments 
in which more than 2 groups were included, one-way analysis of variance 
(ANOVA) followed by Fisher’s least square difference test (LSD) was used to 
evaluate the results. Student’s t-test was used to test for statistical difference in 
experiments consisting of 2 groups. Results were considered statistically 
significantly different for p-values below 0.05. Unless otherwise specified, results 
are given as mean ± standard error of the mean (SEM). Outliers were identified by 
Dixon’s Q-test at a 95% confidence level. 
 
 
 
 
 
 
 
 
Blood collection and blood glucose determination 
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3 RESULTS 
3.1 IL-1β effects on glucose and corticosterone blood levels are 
MyD88-dependent 
The aim of these experiments was to investigate if the effect of IL-1 on glucose 
and corticosterone blood levels is dependent on the MyD88-signalling pathway. 
Although most of the effects exerted by IL-1β are mediated by this pathway, it has 
been shown relatively recently that an IL-1β MyD88-independent, Akt-kinase 
signalling mechanism exists in neurons in the anterior hypothalamus (Davis et al., 
2006). Furthermore, an IL-1RI-independent effect of IL-1β on ischemic brain 
damage has been demonstrated (Diem, 2003). Thus, the response of MyD88 KO 
mice to IL-1β administration on glucose and corticosterone blood levels was 
compared to that of wild type mice (C57BL/6J). Additionally, the capacity of insulin 
to induce hypoglycemia in MyD88 KO mice was studied simultaneously in another 
group of animals. 
3.1.1 No effect of IL-1β on blood glucose levels in MyD88 KO mice 
The absolute glucose concentrations are shown in figure 7. Since there was a 
statistically significant difference in basal glucose levels between WT (201±27.62 
mg/dl) and MyD88 KO mice (168.77±4.44 mg/dl); t33= 3.869, p<0.001) 
comparisons were done expressing the results as percent of the concentration of 
glucose at time 0 of each corresponding mouse. For a better understanding, only 
the significant differences at basal levels are marked in figure 7. 
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Figure 7 Effect of IL-1β on glucose levels. MyD88 KO and C57 BL/6J (WT) mice were 
randomized into 6 experimental groups: MyD88 KO mice received IL-1β (n=9), insulin (n=3) or 
vehicle alone (n=10). Correspondingly, WT mice received IL-1β (n=4), insulin (n=4), or vehicle 
alone (n=5). Blood glucose was measured at the times indicated in the curves. Each point in the 
curve represents the means ± SEM of the determinations performed in the number of the mice per 
group mentioned above. #p<0.05 vs. vehicle WT, *p<0.05 vs. Insulin WT, +p<0.05 vs. IL-1 WT 
 
Confirming previous observations, IL-1β induced a profound and long-lasting 
hypoglycemia in WT mice. The levels of glucose in mice that received IL-1 were 
significantly lower than in vehicle-injected mice at times 2, 4, 6 and 8 hours after 
injection (Figure 8A). Insulin-injected WT mice showed significantly lower blood 
glucose levels than vehicle injected animals only at time 2. No significant 
differences were observed thereafter (Figure 8A). 
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A WT mice 
 
B MyD88 KO mice 
 
Figure 8 Effect of IL-1 on glucose levels in WT mice (Panel A) and MyD88 KO mice (Panel 
B). Blood glucose was measured at the times indicated in the curves. Results are expressed as 
percent of the corresponding time 0 for each individual mouse. Each point in the curves 
represents the mean ± SEM of the determinations performed in the number of mice per group 
indicated in the legend of Figure 7. + p<0.05 vs. vehicle *p<0.05 vs. insulin, # p<0.05 vs. IL-1 
and vehicle 
 
Conversely, IL-1β did not induce hypoglycemia in MyD88 KO mice (Figure 8B). 
Insulin injection in MyD88 KO mice resulted in a decrease in blood glucose levels 
at times 2, 4, 6 and 24 (Figure 8B). All 6 groups are shown superimposed in one 
graph in figure 9, in which only the statistically significant differences between the 
two genotypes that received the same treatment, are indicated. IL-1β-injected WT 
animals showed a statistically significant decrease in blood glucose as compared 
to IL-1β- injected MyD88 KO animals 2, 4, 6 and 8 hours after injection. There 
were no significant differences in glucose blood levels between MyD88 KO and 
WT mice following insulin injection. Vehicle-injected MyD88 KO animals showed 
statistically significantly increased blood glucose levels compared to vehicle-
injected C57BL/6J mice 2, and 6 hours after injection when results are expressed 
as percent of their corresponding time 0. When the means of the absolute glucose 
values of these two groups are compared, there is only a difference at time 0 
(independent sample t-test: t13=3.163, p=0.007). There are no significant 
differences at any other time between vehicle-injected WT and MyD88KO 
animals. These results clearly show that IL-1β-induced hypoglycemia is MyD88-
dependent. 
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Figure 9 Blood glucose levels, expressed as percentage of time 0, following IL-1 or insulin 
injection into WT and MyD88 KO mice. The Results are expressed as percent of the glucose 
concentration determined at time 0 for each individual mouse. Each point in the curves represents 
the mean ± SEM of the determinations performed in the number of mice per group indicated in the 
legend of Figure 7. Since the groups differed significantly in the absolute basal blood glucose 
concentration, comparisons were done with the results expressed as percentage of their 
corresponding time 0 values. Only statistically significant differences between the groups that 
received the same injection are shown. # p<0.05 vs IL-1 KO; + p<0.05 vs vehicle KO 
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3.1.2 No effect of IL-1β on corticosterone blood levels in MyD88 KO 
mice 
To explore if the effect of IL-1β on the HPA axis is also dependent on MyD88 
signalling, corticosterone plasma levels were determined in the same groups of 
animals mentioned above. Confirming previous observations, IL-1β-injected 
C57BL/6J animals showed a marked increase in plasma corticosterone levels, as 
compared to vehicle- and insulin-injected animals 2, 4 and 6 hours after injection 
(figure 10A). Insulin-injected WT mice showed significantly higher blood 
corticosterone levels 2 hours after injection as compared to vehicle-injected WT 
mice (figure 10A). Plasma corticosterone levels in IL-1β-injected MyD88 KO mice 
did not differ from those of MyD88 KO animals that received insulin- or vehicle-
injection (Figure 10B). 
 
A WT mice 
 
B MyD88 KO mice 
Figure 10 Effect of IL-1β on plasma corticosterone levels in C57BL/6J mice (Panel A) and 
MyD88 KO mice (Panel B). Corticosterone concentrations were determined by ELISA in plasma 
of the same mice as shown in Figure 7. Each point in the curves represents the mean ± SEM of 
the determinations performed in the number of the mice per group mentioned in the legend of 
figure 7. # p<0.05 vs. insulin;    + p<0.05 vs. Vehicle 
 
For better comparison, the plasma corticosterone concentrations of the animals of 
both genotypes that received the same treatment are shown in figure 11. There 
was no difference in corticosterone plasma levels between insulin-injected WT 
and KO mice or between vehicle-injected WT and KO mice at any of the time 
points studied (Figure 11A and B). IL-1β-injected WT animals showed statistically 
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significant higher corticosterone plasma levels than IL-1β-injected MyD88 KO 
animals 2, 4 and 6 hours after injection (Figure 11C).  
 
A Vehicle-injected mice B Insulin-injected mice 
 
C IL-1β-injected mice 
 
Figure 11 Plasma corticosterone levels in 
vehicle-injected (Panel A), insulin-
injected (Panel B) and IL-1β-injected 
(Panel C) MyD88KO and WT mice. The 
results of corticosterone concentrations in 
plasma of WT and MyD88 KO mice of figure 
10 are depicted superimposed for better 
comparison. The mice of both genotypes 
received the indicated treatment.  # p<0.05 
vs. WT 
 
 
3.2 Pharmacological inhibition of MyD88 signalling does not 
influence IL-1β-induced hypoglycemia, but affects basal 
glucose levels 
This experiment was designed to examine if pharmacological inhibition of MyD88 
signalling could prevent the changes in glucose and corticosterone plasma levels 
induced by IL-1β. C57 BL/6J mice received the MyD88 inhibitor IMG2005 injected 
i.p. one hour prior to i.p. IL-1β injection, as proposed by the protocol of Van 
Tassell et al. (Van Tassell et al., 2010), and IL-6 plasma levels were determined 4 
hours after IL-1β injection. The non-inhibiting control peptide was injected as 
control. 
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3.2.1 IMG2005 injection does not affect IL-6 levels 
As described, the design of this experiment followed the protocol of Van Tassel et 
al. (Van Tassell et al., 2010). In this publication, IL-6 production was used as a 
surrogate to evaluate the effect of MyD88 inhibition by IMG2005 on IL-1-mediated 
effects. Thus, to control if MyD88 inhibition was successful, IL-6 levels in plasma 
were determined 4 hours after injection of the control peptide or the inhibitor and 
three hours after IL-1β-injection. The results obtained in the experiments 
performed in this work failed to reproduce the effect of IMG2005 reported by Van 
Tassell (IL-6 concentration (ng/dl): control peptide + IL-1β: 0.63 ± 0.34; n=4; 
Inhibitor + IL-1β:  0.41 ± 0.34 ng/dl; n=4). An independent sample t-test showed 
no statistically significant difference in the IL-6 concentration in plasma between 
the two groups (t6=-0.597, p=0.573).  
3.2.2 IMG2005 affects basal glucose concentrations but not IL-1β-
induced hypoglycemia 
Figure 12 shows absolute blood glucose values of WT mice that received the 
treatments described. Basal glucose levels differed significantly between the 
various groups (Figure 12, time 0). Due to the design of the experiment it was not 
possible to detect the significance of the difference during the experiment. Thus, a 
re-distribution of the animals to abolish the difference at basal levels was not 
possible. Therefore, glucose concentrations were calculated as percent of the 
basal concentration in each individual mouse.  
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Figure 12 Blood glucose levels in IMG2005- and IL-1β-injected animals. C57 BL/6J mice were 
randomised into the following groups: IMG2005 and IL-1β (Inh+IL-1, n=11), IMG2005 and vehicle 
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(Inh+Veh, n=7), control peptide and IL-1β (CP+IL-1, n=11), control peptide and vehicle (CP+Veh, 
n=7). After collecting blood and determining blood glucose, animals received either IMG2005 or 
control peptide i.p. One hour later, after collecting blood and determining blood glucose 
concentrations, animals received IL-1β or vehicle also injected i.p. Additional blood samples were 
collected at the times indicated in the figure and glucose was determined. Each point in the curves 
represents the mean blood glucose concentration ± SEM determined in the number of animals 
mentioned above. The inh + veh group showed a statistically significant lower basal blood glucose 
concentration as compared to all the other groups. # <0.05 vs Inh + Veh 
 
Blood glucose levels decreased markedly following IL-1β injection into mice that 
received control peptide, as well as in those that received the inhibitor (Figure 13) 
and animals in both groups developed a statistically significant hypoglycemia after 
IL-1β injection as compared to their corresponding controls. This hypoglycemia 
was still observed 9 hours after the first injection, i.e. 8 hours after IL-1β injection. 
There was no significant difference between the CP + IL-1β group and the Inh + 
IL-1β group when results were calculated as percent of the basal levels. However, 
3 and 5 hours after the first injection, mice that received the inhibitor and vehicle 
alone (inh + veh) developed a statistically significant hyperglycaemia compared to 
mice that received the control peptide and vehicle alone (CP + veh). No significant 
differences between these two groups were detected at later time points (Figure 
13). 
Figure 13 Effect of IMG2005 on blood glucose of IL-1β and vehicle-injected WT mice. 
Animals were randomized into the groups indicated in the legend of Figure 12. After determining 
basal glucose values, mice were injected i.p. either with IMG2005 or with the control peptide. One 
hour later glucose values were determined again and either IL-1β or vehicle was injected i.p. Each 
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point in the curve represents the mean of blood glucose concentrations calculated as percent of 
the time 0 ± SEM of each individual animal. # p<0.05 vs. CP+Veh + p<0.05 vs Inh+Veh and 
CP+Veh 
3.2.3 IMG2005 does not influence plasma corticosterone levels 
As can be seen in figure 14, prior treatment with IMG2005 did not result in 
statistically significant differences in the concentration of corticosterone in plasma 
of animals that received vehicle nor the elevation in corticosterone levels induced 
by IL-1 administration, at any of the time points studied.   
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Figure 14 Influence of IMG2005 administration on blood corticosterone levels. C57BL/6J 
animals were randomised into the groups as indicated in figure 16. The group size was 7 for all 
groups, since the plasma of two mice of each inhibitor-injected group was used for IL-6 
determination. Blood was collected at the times indicated above and corticosterone determined 
with an ELISA. Each point in the curve represents the means of plasma corticosterone 
concentration ± SEM determined in the respective group. # p<0.05 vs. CP+Veh +p<0.05 vs 
Inh+Veh 
3.3 IL-1β injection affects brain energy metabolism 
The objective of these experiments was to investigate the in vivo effect of IL-1β on 
brain energy metabolism, and to compare it with that of insulin. Therefore cerebral 
magnetic resonance spectroscopy for semi-quantitative determination of Cre, Lac  
and NAA in relation to Cho was performed in groups of mice that received either 
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the vehicle alone, IL-1β or insulin. Additionally, glucose and corticosterone 
concentrations in blood were determined before and after each MRS scan. 
3.3.1 Changes in blood glucose concentrations after insulin and 
vehicle injection but not after IL-1β injection during the MRS 
procedure 
Two hours after injecting IL-1β (0.1 µg) or insulin (4 U/kg b.w.) and immediately 
before the second MRS determination, blood glucose levels significantly differed 
from those of the mice that received the vehicle alone (Figure 15A). To keep 
insulin induced-hypoglycemia at comparable glucose levels to that of IL-1β-
induced hypoglycemia, a second injection of insulin was necessary four hours 
after the first one. The same degree of hypoglycemia was also observed in IL-1- 
and insulin-injected mice at later time points (4, 6 and 8 hours) when glucose 
levels were evaluated before performing the corresponding MRS determination. 
However, when glucose levels were determined immediately after each MRS scan 
(which implied ca. 35 minutes of isoflurane narcosis) it was evident that the 
insulin-injected animals had a more profound hypoglycemia than those mice that 
had received IL-1 (figure 15B). 
 
A Before MRS scan 
 
B After MRS scan 
 
Figure 15 Blood glucose of IL-1-, insulin- and vehicle injected animals before (Panel A) and 
after (Panel B) each MRS scan. Blood samples were collected and glucose determined before a 
basal cerebral MRS scan was performed (time 0). A second determination of glucose levels and 
blood collection was performed immediately after MRS data were acquired, and animals received 
randomly either IL-1β (n=7), insulin (n=9) or vehicle (n=9) injected i.p. Further scans followed as 
described in 2.5.3. Blood was collected and glucose determined directly before and after each 
scan. Each point in the curve represents the mean blood glucose levels ± SEM. Two hours after 
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IL-1β- and insulin administration, and before every MRS scan, animals showed hypoglycemia as 
compared to vehicle-injected animals (Panel A). Blood glucose values after MRS scan differed 
statistically significantly between all three groups. Vehicle-injected animals showed 
hyperglycaemic levels, whereas mice of the IL-1β group showed hypoglycaemic values. Even 
lower glucose values could be detected in insulin-injected animals (Panel B). # p<0.05 vs. vehicle; 
+ p<0.05 vs. insulin 
 
The comparison of glucose concentrations before and after MRS determinations 
showed that blood glucose statistically significantly increased in the control group 
(figure 16A), while it decreased in insulin-injected animals (figure 16B) and did not 
change in the IL-1β-injected group (figure 16C) during 35 minutes of MRS 
procedure. 
A Vehicle-injected mice 
 
B Insulin-injected mice 
 
C IL-1-injected mice 
 
Figure 16 Glucose levels in vehicle-injected 
(Panel A), insulin-injected (Panel B) and IL-
1β-injected (Panel C) WT mice before and 
after MRS scan. The graph shows blood 
glucose values of WT mice before (bef) and 
after (aft) 35 minutes of MRS procedure. Mice 
were injected with either vehicle, insulin or IL-1β 
immediately after basal MRS scan. Each point 
in the curve represents the mean blood glucose 
± SEM determined in the number of animals 
mentioned in the legend of figure 17. The figure 
shows that blood glucose concentrations of 
vehicle-injected mice increased (Panel A), 
whereas those of insulin-injected animals 
decreased (Panel B) and those of IL-1β-injected 
mice were not influenced (Panel C) during 35 
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minutes of MRS procedure. # p<0.05 vs. bef 
 
To control if the decrease of blood glucose levels in insulin-induced hypoglycemia 
during the 35 minutes of MRS acquisition was caused by isoflurane narcosis, a 
separate group of animals was subject to 35 minutes of isoflurane narcosis, 
following exactly the same procedure but without MRS recording. Blood glucose 
was determined before and after narcosis and the procedure was repeated four 
times, at intervals of two hours. 
Figure 17 shows glucose concentrations in blood of vehicle- and insulin-injected 
mice respectively, before and after narcosis. Vehicle-injected mice showed 
hyperglycaemic levels after 35 minutes of narcosis, whereas a further decrease in 
blood glucose concentrations could be observed following the same procedure 4 
and 6 hours after insulin injection. Although only 3 mice per group were included, 
the effect of the narcosis was statistically significant. It was concluded that the 
changes in glucose blood levels observed during the scans were not due to the 
MRS procedure but rather to the narcosis itself. 
A Vehicle-injected mice B Insulin-injected mice 
Figure 17 Blood glucose of vehicle-injected mice after 35 minutes of isoflurane narcosis  
C57 BL6/J animals were randomized into a vehicle-injected control group (n=3) and an insulin-
injected group (n=3). Blood glucose was determined and animals underwent 35 minutes of 
isoflurane narcosis. Afterwards blood glucose was determined again. This procedure was 
repeated 4 times, at intervals of two hours. This figure shows blood glucose values before 
narcosis (bef) compared to those after narcosis (aft) of vehicle-injected (Panel A) and insulin-
injected (Panel B) mice. Each point in the curves represents the mean blood glucose levels ± 
SEM. Blood glucose values of vehicle injected animals increase statistically significantly after 35 
minutes of narcosis, whereas those of insulin-injected animals decreased after narcosis 4 and 6 
hours after the first insulin-injection. # p< 0.05 vs. bef 
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3.3.2 Plasma corticosterone concentrations increase during the MRS 
scan 
Plasma corticosterone levels significantly increased after IL-1β injection as 
compared to those of insulin- or vehicle-injected animals. This effect was 
observed before (figure 18A) as well as after (figure 18B) each MRS with 
exception of the last MRS scan, after which there was no statistical significant 
difference between the groups. 
A  Before MRS scan B After MRS scan 
 Figure 18 Plasma corticosterone levels before (Panel A) and after (Panel B) MRS scan. 
Plasma corticosterone levels were determined in the same mice as used for glucose 
determinations. As indicated in figure 15 these animals received either IL-1β (n=7), insulin (n=9) or 
vehicle (n=9) i.p. Blood was collected before and after each MRS scan. The graph shows plasma 
corticosterone levels before (panel A) and after (panel B) MRS scans. Plasma corticosterone 
concentration was determined by ELISA. Each point in the curve represents the mean plasma 
corticosterone ± SEM. IL-1β-injected animals showed increased plasma corticosterone levels after 
MRS at every time after injection, apart from the last MRS scan performed. # p<0.05 vs. Insulin 
and Control 
 
When comparing corticosterone levels before and after MRS during the first scan, 
it can be observed that corticosterone levels increased in all groups during the 
MRS procedure. This rise becomes less prominent with each following MRS scan 
and it is no longer statistically significant at time 8 in the mice that received vehicle 
(figure 19A), at time 6 in the insulin-injected group (figure 19B) and at time 4 in 
mice that received IL-1β (figure 19C). 
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A Vehicle-injected mice 
 
B Insulin-injected mice 
 
C IL-1β-injected mice 
 
Figure 19 Plasma corticosterone levels in 
vehicle-injected (Panel A), insulin-injected 
(Panel B) and IL-1β-injected (Panel C) mice 
before and after MRS procedure. The results 
of corticosterone concentrations in plasma 
before (bef) and after (aft) MRS scan of figure 
18 are depicted superimposed for better 
comparison.    # p<0.05 vs. aft 
 
 
3.3.3 Differences in brain metabolites between IL-1β-, Insulin- and 
vehicle-injected animals 
To evaluate brain energy metabolism under the influence of IL-1β, MRS brain 
scans were performed, as described in chapter 2.3.6. NAA, Cre, Lac and Cho 
were identified in the spectra. Figure 20 shows an example of the spectrum 
obtained before any injection (time 0). The integrals of the peaks are proportional 
to the concentration of the corresponding metabolite. To avoid deviations due to 
possible changes in the magnetic field, the metabolites are commonly divided by 
the integral of the Cre peak. However, since creatine levels may be affected by 
changes in energy metabolism, Cho was used as reference because it is not 
considered to be altered during changes in energy metabolism. 
0
5
10
15
20
25
30
35
C
o
rti
co
st
e
ro
n
e
 
(µg
/d
L 
Pl
a
sm
a
)
0 2 4 6 8
befaft
Time (hs after 1st injection)
# # 
# # 
0
5
10
15
20
25
30
35
C
o
rti
co
st
e
ro
n
e
 
(µg
/d
L 
Pl
a
sm
a
)
0 2 4 6 8
befaft
Time (hs after 1st injection)
# 
# 
# 
0
5
10
15
20
25
30
35
Co
rti
co
st
e
ro
n
e
 
(µg
/d
L 
Pl
a
sm
a
)
0 2 4 6 8
befaft
Time (hs after 1st injection)
# 
# 
  53 
 
Figure 20 Example of an MR spectrum obtained from a non-injected mouse. The white line 
represents the spectrum acquired and the red line indicates the corresponding curve-fit. I: Integral 
 
The ratios NAA/Cho, Cre/Cho and Lac/Cho did not statistically differ between the 
mice assigned to the different treatment groups. 
The difference between NAA/Cho, Cre/Cho and Lac/Cho ratios at each time point 
and the corresponding ratio at time 0 for each individual mouse was used for 
further statistical analyses. 
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Mice of the IL-1β-treated group showed a significantly increased NAA/Cho ratio 
relative to their initial values at 8 hours as compared to those of the insulin group. 
In the insulin-treated group this difference was negative and statistically 
decreased as compared to the difference of the NAA/Cho ratio relative to initial 
values in the control group (figure 21).  
 
Figure 21 Changes in the differences in NAA/Cho ratios after IL-1, insulin and vehicle 
injection. C57BL/6J animals were randomised into 3 groups as mentioned in figure 18. MRS was 
obtained as described in 2.3.6. The MRS obtained before any injection was defined as basal 
determination (time 0). Each point in the curves represents the mean ± SEM of the difference 
between the NAA/Cho ratio at a given time and the ratio at time 0 for each individual mouse. # 
p<0.05 vs. vehicle, + p<0.05 vs. insulin 
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Regarding Cre, the differences in the Cre/Cho ratios were significantly increased 
in the IL-1β-treated group at 4 and 6 hours as compared to the control group and 
at 6 and 8 hours as compared to the insulin-treated group (Figure 24).  
 
 
Figure 22 Changes in the difference of Cre/Cho ratios after IL-1, insulin and vehicle 
injection. As described in legend to figure 21, but showing the Cre/Cho ratio at a given time and 
the ratio at time 0 for each individual mouse. Each point in the curve represents the mean ± SEM # 
p<0.05 vs. vehicle, + p<0.05 vs. insulin 
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The differences in the Lac/Cho ratios were significantly higher in IL-1β-treated 
mice as compared to those of the vehicle-injected mice 6 hours after injection 
(figure 23). 
 
Figure 23 Changes in the difference of Lac/Cho ratios after IL-1, insulin and vehicle 
injection. As described in legend to Figure 21, but showing the Lac/Cho ratio at a given time and 
the ratio at time 0 for each individual mouse. Each point in the curves represents the mean ± SEM. 
# p<0.05 vs. vehicle 
 
In conclusion, the differences in the ratios NAA/Cho, Cre/Cho and Lac/Cho were 
in general elevated in IL-1β-injected mice as compared to those of vehicle- and/or 
insulin-injected animals. These differences were statistically significant between 4 
and 6 hours after injection, and in part were still detectable after 8 hours. 
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4  DISCUSSION 
4.1 IL-1β-induced hypoglycemia and the stimulation of the HPA-
axis depend on MyD88-mediated signalling 
As shown in chapter 3.1.1, IL-1β-induced hypoglycemia is dependent on 
mechanisms that function via MyD88 signalling. Confirming previous results, IL-1β 
injection into C57BL/6J resulted in a profound hypoglycemia and in the stimulation 
of the HPA axis (del Rey and Besedovsky, 1987; del Rey and Besedovsky, 1992; 
del Rey et al., 2006). However, neither hypoglycemia nor increased corticosterone 
levels were observed after IL-1β administration into MyD88-deficient mice. These 
results clearly show that the mentioned effects of IL-1β are mediated by this 
universal adapter protein. As explained in chapter 1.2.4, it remains still unclear to 
what extent peripheral and cerebral effects contribute to IL-1β-induced 
hypoglycemia. Also, the signalling mechanisms that are involved in the effects that 
IL-1β exerts at brain levels are still controversial (Dantzer, 2009). It is therefore 
possible that the central effect of IL-1β that results in hypoglycemia is itself not 
MyD88-dependent, but its transmission across the blood-brain-barrier (BBB). To 
further elucidate this question, A. Lörwald showed in her diploma thesis that i.c.v. 
injection of 5ng of IL-1β induces hypoglycemia in heterozygous MyD88+/- animals 
but not in MyD88 KO animals (Lörwald, 2012), thus providing first evidence that 
MyD88 in the brain is essential for direct effects of IL-1-induced hypoglycemia. 
Confirming the results of former studies (Gosselin and Rivest, 2008; Ogimoto et 
al., 2006), no increase in corticosterone plasma levels were observed in MyD88 
KO mice. It cannot be excluded that the response of the HPA axis in MyD88 KO 
animals is impaired due to general impossibility to release corticosterone beyond 
a certain level in these animals. However, this seems to be unlikely for various 
reasons: a) Vehicle-injected MyD88 KO mice showed no significant different 
corticosterone plasma levels when compared to WT mice. B) Corticosterone 
plasma levels showed the typical circadian rhythm in both KO and WT mice.  
Since cerebral MyD88 expression is necessary for the hypoglycaemic effects of 
IL-1β, the same might apply for the activation of the HPA-axis (Gosselin and 
Rivest, 2008). 
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The results derived from the pharmacological inhibition of MyD88 are less clear. 
There are very few MyD88 inhibitors available, and IMG2005, the inhibitor used in 
the studies reported here, did not abrogate the effects of IL-1β at the 
concentration administered. It has been reported that the same concentration of 
IMG2005 as used in the studies shown here can inhibit IL-6 production and cardial 
dilatation after ischemia (Van Tassell et al., 2010). However, neither IL-6 release 
nor IL-1β-induced hypoglycemia or the activation of the HPA axis were influenced 
by this inhibitor in our studies. As described in this work and by others as well, 
corticosterone blood levels do not increase after IL-1β injection into MyD88 KO 
mice (Gosselin and Rivest, 2008; Ogimoto et al., 2006). However, Ogimoto et al. 
demonstrated that MyD88 KO mice show IL-6 and IL-10 levels comparable to 
those of WT mice after LPS injection. Thus, it is possible that IL-1-induced IL-6 
production is not, or not alone, dependent on MyD88. Furthermore, it is possible 
that the dose of IL-1β applied was too high in relation to the IMG2005 dose. Since 
stimulation of very few IL-1RI is enough to activate intracellular signalling 
(Stylianou et al., 1992), almost all TIR domains of IL-1RI-IL-1RacP complexes 
must be blocked in order to inhibit IL-1β signalling effectively. (Ogimoto et al., 
2006)  
However, it is noteworthy that injection of the inhibitor alone resulted in 
hyperglycaemia 3 and 5 hours after administration. This indicates that MyD88-
signalling may play a role in basal glucose homeostasis under physiological, 
healthy conditions. In support of this possibility are other studies showing that 
IMG2005 injected i.c.v. causes an even more marked hyperglycaemia (Lörwald, 
2012). Thus, further experiments with higher doses of IMG2005 injected 
peripherally or the use of other MyD88 inhibitors are needed to investigate the role 
of IL-1 or other members of the TIR-family on glucose regulation under 
physiological conditions. 
The same considerations apply to the lacking of effect of IMG2005 administration 
on IL-1β-induced increase in corticosterone levels. As expected, IL-1β injection 
resulted in statistically significant increased corticosterone blood levels as 
compared to vehicle-injected animals, but IMG2005 did not block this effect. 
Experiments using higher concentrations of IMG2005, injected i.p. and i.c.v. are 
necessary to further investigate the involvement of MyD88 in IL-1β-induced 
activation of the HPA-axis.  
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4.2 Changes in glucose and corticosterone levels during MRS 
The procedures needed to acquire the MRS data, including narcosis, induced an 
increase in glucose blood levels in vehicle-injected mice. Conversely, insulin-
injected animals showed a further decrease in blood glucose concentration after 
exposure to approximately 35 minutes of MRS and isoflurane narcosis during the 
acquisition of the MRS data. To investigate if these effects were due to isoflurane 
inhalation, insulin- and control-injected animals received 35 minutes of isoflurane 
anaesthesia alone. This treatment resulted in effects comparable to those 
observed in mice that underwent MRS and narcosis. The increase in blood 
glucose levels observed in vehicle-injected mice is most likely caused by a stress 
response to the narcosis, blood collection and injection. 
Furthermore, isoflurane has a pharmacologic effect on glucose metabolism. It has 
been reported that patients undergoing isoflurane narcosis show impaired insulin 
secretion and hyperglycaemia (Diltoer and Camu, 1988). Isoflurane increases 
blood glucose levels by decreasing the sensitivity of pancreatic KATP-channels to 
ATP, thus leading to hyperpolarisation and decreased insulin secretion after a 
glucose load (Tanaka et al., 2011). Furthermore, it has been shown that volatile 
halogenated anaesthetics lead to enhanced activation of KATP-channels in smooth 
muscle tissue and cardiomyocytes during decreased intracellular ATP 
concentration (Fujimoto et al., 2002; Tanaka et al., 2007). However, it is not yet 
known how isoflurane interacts with cerebral KATP-channels or which effects are 
elicited in states of hypoglycemia. Since isoflurane crosses the BBB, it is possible 
that it has an effect on hypothalamic KATP-channels in GE-neurons, which are of 
the same subtype as pancreatic KATP-channels (Seino and Miki, 2003). If 
isoflurane leads to a relative hyperpolarisation of GE-neurons, as it does in 
pancreatic β-cells, this would lead to an increased hypoglycaemic 
counterregulation. As described in chapter 1.5, hyperpolarisation of hypothalamic 
GE-neurons leads to an increase of hypoglycaemic counterregulatory hormones. 
In our experiments, isoflurane application enhanced the hypoglycaemic effects of 
insulin resulting in very low blood glucose levels (30mg/dl or less). One possibility 
is that isoflurane impairs not only insulin release, but also interferes with counter 
regulatory mechanisms such as the release of monoamines, glucocorticoids or 
glucagon. Evidence exists that isoflurane might reduce adrenalin levels in humans 
(Diltoer and Camu, 1988) and that it does not influence glucagon levels 
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(Lattermann et al., 2003; Schricker et al., 2004). However, corticosterone levels 
were increased under isoflurane anaesthesia. Another possible explanation would 
be that isoflurane acts synergistically at the effector cells, mainly in skeletal 
muscle, fat and liver either by increasing the affinity of the insulin receptor to 
insulin or by enhancing anabolic effects of insulin. 
A most interesting observation within the context of this work is that IL-1β-injected 
animals showed comparable levels of blood glucose before and after narcosis, 
although they were subjected to the same experimental procedure as those that 
received insulin or vehicle alone. These results provide a further argument in 
support of the hypothesis that IL-1β resets glucose homeostasis at a 
hypoglycaemic set-point, as discussed in chapter 1.2.4. The corticosterone levels 
of insulin- and vehicle-injected animals showed the largest increase after the first 
MRS scan. This is most likely an expression of a stress-induced activation of the 
HPA-axis. The increase in corticosterone blood levels during the MRS scans 
became gradually less pronounced during the course of the experiment until the 
difference of the corticosterone levels before MRS procedure compared to those 
after MRS procedure was no longer statistically significant after 6 hours. This is 
probably due to adaptation to the experimental procedure. 
IL-1β-injected animals showed an increase in corticosterone levels during the first 
MRS scan. Elevated levels of corticosterone were also observed at the second 
MRS 
scan, as expected, due to IL-1β-induced activation of the HPA-axis, which peaks 
2 
hours after injection and decreases thereafter. The increase in corticosterone 
concentration is limited by the capacity of the adrenal gland. Thus, corticosterone 
concentrations did not increase further at the third MRS scan. 
4.3 IL-1β affects brain energy metabolism: differences with the 
effects of insulin 
The main aim of these experiments was to evaluate cerebral energy metabolism 
under IL-1β-induced hypoglycemia and to compare it with the effects of a 
comparable hypoglycemia induced by insulin. It was not possible to detect 
glucose directly with the MRS device available, since the H1 MR glucose signal is 
overlain by the water signal. Therefore Lac, Cre and NAA were used as 
  61 
parameters to evaluate brain energy metabolism. Cho, the fourth metabolite 
determined, is not considered to play a role in neuronal energy metabolism and 
was therefore used as a reference. As discussed in chapter 1.4, Lac is a fuel for 
neurons, derived mainly from anaerobic glycolysis, whereas Cre and NAA 
contribute to support neuronal energy metabolism. Cre is involved in the 
phosphocreatine/creatine-kinase/creatine system that participates in the high 
energy phosphate metabolism of tissues with high and fluctuating energy demand 
(Bittsansky et al., 2012; Schwarcz et al., 2003; Wallimann et al., 1992; Wyss and 
Kaddurah-Daouk, 2000). 
According to the classical view, ketone bodies and amino acids, such as 
glutamate and aspartate, are the main source of energy for the brain during 
severe insulin-induced hypoglycemia and hypoglycaemic coma (Agardh et al., 
1978; Sutherland et al., 2008). However, there is evidence that during increased 
neuronal activity, energy consumption or hypoglycemia, astrocytes shuttle 
glucose-derived lactate or pyruvate to neurons to cope with the emerged fuel-gap 
(Brown and Ransom, 2007; Brown et al., 2005; Suh et al., 2007).  
Regarding the changes in the metabolites evaluated from basal conditions until 8 
hours after injection, IL-1β-injected mice showed an increase in all parameters 
measured as compared to vehicle-injected animals (Lac/Cho), insulin-injected 
animals (NAA/Cho) or both (Cre/Cho). The increase reached statistical 
significance 4-8 hours after injection. These results suggest that, under the 
influence of IL-1β, brain energy metabolism is enhanced even though blood 
glucose levels are decreased. A possible explanation for this effect is that IL-1β 
increases the availability of energy substrates to neurons, thus “hiding” the 
peripheral hypoglycemia to the brain. Most likely, this would be achieved by an 
increased neuronal uptake of either glucose, or lactate, or both. It has been 
previously shown, that the mechanisms that counterregulate hypoglycemia, as 
represented by increased plasma concentrations of corticosterone and glucagon 
are no longer observed 4 to 8 hours after IL-1β injection (del Rey and 
Besedovsky, 1987; Ota et al., 2009). This coincides with the time interval when 
the main differences in the metabolite ratios are observed in the experiments 
described here, thus providing further evidence to the hypothesis, that IL-1β-
induced hypoglycemia is not detected by the brain. Furthermore, MyD88 KO mice, 
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which do not develop hypoglycemia after IL-1β injection, do not show changes in 
the metabolite ratios comparable to those of WT mice (Lörwald, 2012).  
 As mentioned in chapter 1.5, infusion of glucose or lactate in the hypothalamus 
induces hypoglycemia and inhibits hypoglycaemic counterregulation by changing 
the ADP/ATP-ratio in GE- and GI-neurons (Borg et al., 1997; Borg et al., 2003; 
Song and Routh, 2005). It has already been reported that IL-1β induces glucose 
uptake and utilization in astrocytes (Vega et al., 2002), but no data is available 
concerning neurons. It is also not known if IL-1β affects lactate metabolism in 
neuronal or glial cells. Another possibility would be that neurons take up lactate 
provided by astrocytes as proposed by the ANLS-hypothesis (see 1.4).  
Since the concentrations of NAA and Cre rise in states of increased energetic 
metabolism (Bittsansky et al., 2012; Clark, 1998; Moffett et al., 2007; Wyss and 
Kaddurah-Daouk, 2000), the relative Cre and NAA increase might reflect an 
indirect effect of IL-1 due to an increased energy metabolism.  
Interestingly, no comparable differences were detected in the metabolites 
between insulin- and vehicle-injected animals. It could have been expected that 
cerebral lactate concentration would decrease under insulin-induced 
hypoglycemia. In fact, Rao et al. showed that 60-80 minutes after initiation of 
insulin-induced hypoglycemia, brain lactate concentration decreases (Rao et al., 
2010). However, these experiments were done with 14 day-old pups, which 
suffered a more profound hypoglycemia than the adult animals used in our 
experiments. It has also been reported that a decrease in cerebral lactate 
concentration can be first detected in the hippocampus of the young pups only 
after around 90 minutes of blood glucose values below 50mg/dl (Lewis et al., 
1974; Rao et al., 2010) and in parallel to neuroglycopenia. In the experiments 
described here, the adult animals suffered a comparable hypoglycemia during 35 
minutes only.  
4.4 Conclusion and perspectives 
This study shows that IL-1β-induced hypoglycemia is MyD88-dependent and 
paralleled by an increase in Lac/Cho, Cre/Cho and NAA/Cho ratios. One possible 
interpretation of these results is that, as opposed to the hypoglycemia caused by 
insulin, cerebral energy metabolism is increased during IL-1β-induced 
hypoglycemia. While performing the studies reported in this work, A. Löhrwald 
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showed that no changes in cerebral energy metabolism are detected in MyD88 
KO mice, further indicating the involvement of MyD88-signalling in the mediation 
of IL-1β-induced hypoglycemia (Lörwald, 2012). It is clear, that further studies are 
needed to clarify the role of MyD88 in IL-1β-induced hypoglycemia. For example, 
it would be necessary to evaluate changes in the energy metabolism of 
hypothalamic, glucose-sensing neurons and its surrounding astrocytes. One 
approach would be to use in vitro cultures of cells obtained from WT and MyD88 
KO mice.  
Another aspect that needs detailed investigation to elucidate the mechanisms by 
which IL-1β changes glucose homeostasis at central levels, is to study if GLUT or 
monocarboxylate-transporter expression and incorporation into the cell membrane 
of neurons and astrocytes are affected by the cytokine. 
Here, first evidence was provided that acute blockade of MyD88 leads to 
hyperglycaemia, which was further confirmed by A. Lörwald (Lörwald, 2012). 
Thus, the involvement of MyD88 in the physiological regulation of glucose 
homeostasis needs further investigation. In vivo experiments including i.c.v. 
injections of different antagonists of receptors that signal via MyD88 might help to 
identify the endogenous ligand that plays a role in basal glucose regulation. 
Furthermore, kinetics studies should be performed to investigate at what time after 
i.c.v. injection of IL-1β, maximal hypoglycemia is reached. So far it was only 
shown that IL-1β injected i.c.v. leads to hypoglycemia 4 h after injection (del Rey 
and Besedovsky, 1992). 
How IL-1β leads to an increase in lactate remains to be elucidated by further in 
vivo and in vitro experiments. Due to resolution limits of the methodology used, we 
were only able to evaluate spectroscopically the whole brain. Thus, it would be 
important in future experiments to evaluate smaller, well-defined brain regions, 
such as the hypothalamus. Possible approaches are either enzymatic or HPLC 
determinations of glucose, lactate and ketone bodies in the hypothalamus or 
fluoro-2-desoxy-D-glucose positron emission tomography (FDG-PET) imaging. To 
further clarify the signalling mechanisms by which IL-1β activates the HPA-axis, 
experiments including i.c.v. injection of IL-1β in MyD88 KO mice and i.c.v. 
injection of MyD88 inhibitors into WT mice will be carried out in a following study.  
Previous studies have shown that IL-1β is necessary for sustaining LTP, learning 
and memory, processes that are highly demanding in terms of energy 
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(Besedovsky and del Rey, 2011). This evidence, together with the results reported 
here showing that this cytokine changes brain energy metabolism, allow to 
hypothesise that IL-1 is needed to transfer energy substrates to activated 
neurons, as insulin does in peripheral tissues with high energetic needs. Besides 
its relevance for basic physiology, this might shed a new light on the role of IL-1 in 
neuropsychiatric diseases. So far, the research is focussed on the 
proinflammatory effects of IL-1 in neuropsychiatric diseases such as depression 
(Akhondzadeh et al., 2009; Dinan, 2009) or cognitive impairment (Gemma and 
Bickford, 2007). Since some of the symptoms of these diseases or even their 
aetiology might be explained by local or general impairments of cerebral energy 
metabolism, further investigation of the role of IL-1 in brain energy metabolism in 
pathologic conditions is needed.  
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